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 Embedded Wireless Intracranial Pressure Monitoring Implant at Microwave 
Frequencies 
Usmah Kawoos 
Dr. Arye Rosen, Ph.D 
 
Intracranial Pressure (ICP) monitoring is a significant tool that aids in the management 
of neurological disorders like hydrocephalus, head trauma, tumors, colloid cysts, cerebral 
hematomas etc. ICP is the pressure exerted on the rigid, bony skull by its constituents that are 
brain, cerebrospinal fluid, and the cerebral blood. Increased ICP can lead to brain damage, 
disability, and death. Various modalities have been developed for the monitoring of ICP in 
hospitals and in ambulatory conditions. Currently, only catheter based systems have made it to 
the clinical practice. The catheter based systems can only be used in a hospital setting, and have 
a limited useful life due to drift and risk of infection. 
The motivation for this research was the intent to develop a completely implantable, 
wireless ICP monitoring implant that can provide long-term monitoring of the pressure in 
ambulatory conditions. The uniqueness of this work is accentuated by the ability of the implant 
to transmit at 2.4 GHz. These implants have undergone a battery of tests in the in-vitro and in-
vivo (canine) studies  during which the feasibility of microwave transmission through scalp was 
established. Long-term animal studies were conducted to determine the integrity, 
biocompatibility, and the performance of the implant in a biological environment. Animal 
studies for long durations with epidural implants showed a thickening of the dura mater under 
sensor area. Therefore, the effect of dural thickness on the sensitivity of pressure sensing 
mechanism was simulated. The histo-pathological examination of the tissue specimens that 
were excised at the termination of an animal study showed the presence of lymphocytes, and 
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fibrous tissue which is a normal immunological reaction to a foreign body. These tests did not 
reveal any toxicity due to the presence of the implant. In the animal studies that were conducted 
with sub-dural implants, a correlation coefficient of 0.94 and better was determined between the 
gold standard for ICP monitoring and our implant. In our latest animal study a sub-dural implant 
has been successfully tested in an animal for a duration of one month, thus proving the 
reliability of the implant packaging and its performance for a long-duration ICP monitoring 
application.  This study also underscores the applicability of our ICP implant for monitoring of 











1. Motivation and Introduction 
For more than two centuries the concepts of physics have been applied to the 
intracranial contents. It was in 1783, Alexander Monro - a Scottish anatomist published his 
findings in a monogram [1] that form the basis of many hypotheses and principles described 
thereafter. The key points made by Monro were: 
 i) Skull is a non-expandable rigid case,  
ii) The brain matter is nearly incompressible, 
iii) The volume of blood in a cranial cavity is essentially constant, and 
iv) There has to be a continuous outflow of venous blood from the cranial cavity to make 
room for the inflow of arterial blood.  
Thus, for the first time it appeared in the literature that the volume of blood circulating 
in the cranium remains constant at all times. Monro’s doctrine was later confirmed by Kelly and 
Abercrombie [2] and is popularly known as “Monro-Kelly Hypothesis” or “Monro-
Abercrombie Doctrine’’. However, all of them ignored the presence of cerebrospinal fluid 
(CSF) and assumed that the volume of the cerebral blood swung between the venous and the 
arterial side while the total volume remained constant. It was Francois Magendie, a French 
Physiologist of the 19th century who recognized the significance of CSF and its contribution 
towards the total intracranial volume [3]. He demonstrated a communication between the fourth 
ventricle and the sub-arachnoid space (SAS) through a foramen that became to be known as 
“Foramen of Magendie”. 
Considering that the skull is a rigid vault, with a slightly compressible brain matter and 
an almost fixed volume of blood at any given time, any increase in the volume of CSF is a 
significant factor leading to an elevation of the intracranial pressure (ICP). CSF is constantly 
being produced and absorbed in the cranial system, and it also maintains a circulatory system 
through the ventricles of the brain, SAS, and the spinal canal [4]. An abnormality in the volume 
of CSF can arise due to- i) an imbalance between its production and absorption or ii) an 
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obstruction in its circulatory pathway. The consequences of an elevated ICP can range from 
mild (headache, nausea, vomiting) to severe (brain damage, disability, death) [5].  
A direct motivation to the development of a completely implantable ICP monitoring 
device came from Late. Dr. Samuel Neff, a pediatric neurosurgeon, who experienced a lack of a 
long-term ICP monitoring technique for hydrocephalic children in his clinical practice. He 
collaborated with a team at Drexel University, led by Dr. Arye Rosen and Dr. Mohammad Reza 
Togighi that took up an initiative to work towards the development of an implantable, wireless 
ICP device. 
In the present clinical practices, ICP is monitored by a catheter system in hospital 
settings. A most typical example of such a system is Camino catheter manufactured by Integra 
Life Sciences Inc. A catheter system is a direct and invasive method for the monitoring of ICP 
that presents the risks of infection, patient discomfort, dislodgement of the catheter, and tissue 
damage. It also restricts patient mobility and keeps him/her attached to external monitors. On 
the contrary, an implantable, wireless ICP monitoring device would provide the means of taking 
non-invasive ICP measurements once the device is implanted by a surgical procedure. The 
patients in need of ICP monitoring undergo a surgical procedure for the treatment of any 
underlying cause of abnormal ICP. The ICP device can be implanted as a part of the surgery, 
thus demanding no exclusive preparation for its implantation. In addition to the ease of ICP 
monitoring by non-invasive method, this implantation procedure also offers monitoring of ICP 
in ambulatory conditions along with providing patient comfort. 
This thesis primarily focuses on:  
i) The development of an ICP implant at microwave frequencies,  
ii) Evaluating the biocompatibility of the implant,  
iii) Devising various protocols for experimental testing of the implant in laboratory settings,  
iv) Conducting proof-of-concept and long-term studies in animal models, and 
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v) Performing finite element analysis of the interaction of dura mater with pressure sensing 
membrane.  
As we progressed through this research initiative, various generations of the ICP 
implant were built. The information gathered from each generation was utilized in improving 
the next one. The details of each generation along with the procedures undertaken to ensure the 
biocompatibility of the devices are detailed in Chapter 4 of this thesis. The methods and 
materials, protocols, and results related to in-vitro and in-vivo experimentation are presented in 
Chapter 5 and Chapter 6, respectively. A finite element analysis of the interaction between dura 
mater, scar tissue and the pressure sensing membrane is documented in Chapter 7.  Throughout 
the various developmental stages of this work, it has received a tremendous inflow of 
constructive criticism and inputs from within the team as well as various collaborators and 
reviewers. This has led to the opening of a realm of diverse applications of ICP monitoring as 
diagnostic, therapeutic, and research tool. A brief note of such applications as well as the 
contribution of this thesis is presented in Chapter 8. Chapter 8 also broaches the envisioned 
future work that can be undertaken with the latest generation of the implant.  For the sake of 
completeness, a brief account of neuroanatomy that is directly relevant to the CSF circulation, 











2. Neuroanatomy in Relation to Intracranial Pressure  
An understanding of the central nervous system (CNS) relevant to various aspects 
responsible for the build-up and maintenance of ICP is pivotal to the development of an ICP 
monitoring modality. This chapter presents a description of the ventricular system, 
cerebrospinal fluid, meninges of the brain, and the pathophysiology of intracranial hypertension 
(ICH). 
2.1 Ventricular system 
The CNS contains a series of interconnecting chambers and channels that develop from 
the lumen of the embryonic neural tube. The ventricular system has four ventricles: two lateral 
ventricles, third, and fourth ventricle [6]. The lateral ventricles are relatively large, somewhat 
‘C-shaped’ and are located within the cerebral hemisphere, one on each side. A  lateral ventricle  
has four distinct regions, i.e., anterior horn towards the frontal end, body, posterior horn towards 
the occipital end, and inferior horn towards the temporal end. The lateral ventricles 
communicate with the third ventricle via interventricular foramen or foramen of Monro. The 
third ventricle is a narrow slit-like cavity in the mid brain whose lateral walls are formed by 
thalamus and hypothalamus on either side. The third and fourth ventricles communicate via 
cerebral aqueduct. The fourth ventricle is a wide and shallow, rhomboid-shaped depression 
which is located in the hind brain on the dorsal surface of the brain stem beneath the 
cerebellum. On each side of the fourth ventricle a lateral recess extends towards the lateral side 
of the brain stem and is in continuity with the SAS through a lateral aperture.  Figure 2.1, shows 
a resin cast model of the ventricular system where as ventricles with respect to the surface of  
brain are shown in Figure 2.2.  A number of foramena (holes) interconnect the ventricles and 
connect the ventricles to the SAS. Table 1.1 lists the foramena along with their alternate names 




Figure 2.1. Resin cast of the ventricular system [6]. 
 
 




Table 1.1. The foramena of brain. 
 
2.2 Cerebrospinal fluid  
Cerebrospinal fluid (CSF) fills the ventricles, SAS and the spinal canal of the CNS. In 
humans, the volume of CSF is about 150 ml most of which is contained in the lateral ventricles 
and has a production rate of 20ml/hour [7].  It forms a liquid cushion in and around the brain 
and spinal cord and gets constantly absorbed and replaced. It also provides buoyancy to brain, 
thus preventing it from crushing against its own weight. It has been estimated that 60-70% of 
the CSF is produced by the choroid plexus that are located in the ventricles [8]. The remainder 
of the volume is secreted around blood vessels and ventricular walls. The choroid plexus is 
formed by invagination of vascular pia mater (outer-most meninge of the brain) into the 
ventricular lumen where it assumes a highly convoluted, sponge-like appearance.  The choroid 
plexus enters the third and fourth ventricle through their roofs and the lateral ventricles through 
choroid fissures. 
The CSF flows through the interventricular foramen from the lateral ventricles to the 
third ventricle and continues to the fourth ventricle via cerebral aqueduct. The CSF leaves the 
fourth ventricle through the median and the two lateral apertures to enter cistern magna and 
SAS, respectively. Figure 2.3 depicts the flow of CSF in relation to the SAS and the circulation 
of CSF is indicated by arrows. Some CSF also flows into the spinal canal. Figure 2.4 shows the 
circulation of CSF in CNS. The majority of CSF flows superiorly over the brain to the site of 
reabsorption, i.e., arachnoid villi. CSF is absorbed in to the venous system by passing into the 
Name Alternate Name Connection/Role 
Interventricular 
Foramen Foramen of Monro Lateral ventricles to the third ventricle 
Cerebral Aqueduct Foramen of Sylvia Third ventricle to the fourth ventricle 
Median Aperture Foramen of Magendie Fourth ventricle to cisterna magna 
Lateral Apertures 
(right and left) Foramen of Lushka Fourth ventricle to SAS 
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dural venous sinuses (superior sagittal   sinus). Arachnoid villi are located along the lumen of 
the sinuses and are formed by the invagination of arachnoid mater through the dural layer and 
into the lumen of the sinuses.  A depiction of arachnoid villi is presented in Figure 2.5. 
 
 
Figure 2.3. The relationship of cerebral ventricular system with the subarachnoid space [6]. 
The venous sinuses are the sites of reabsorption because of two reasons:  
i) the hydrostatic pressure in SAS is higher than that of the venous sinuses, and 
ii) the colloid osmotic pressure of blood is greater than that of the CSF. As age progresses, the 






Figure 2.4. Circulation of CSF in the ventricles, subarachnoid space and the spinal canal [7]. 
 
 
Figure 2.5. Presence of arachnoid villi in the venous sinus for reabsorption of cerebrospinal fluid [6]. 
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2.3 Meninges of brain 
The brain and the spinal cord are enveloped by three concentric membranes, also called 
meninges, within the bony cranial vault. The outermost membrane is dura mater, arachnoid 
mater being the middle layer, and pia mater is the innermost membrane that runs along the brain 
parenchyma. The organization of the meninges is described in Figure 2.6. Dura mater is a 
tough, fibrous membrane that is separated from the skull by a narrow extradural space except in 
certain regions like the midline of cranial roof where dura tightly adheres to the skull. Falx 
cerebri and tentorium cerebelli are two large reflections of dura that occupies the fissures 
separating major components of the brain. Falx cerebri lies in the longitudinal fissure, 
separating the two cerebral hemispheres. Tentorium cerebella is a horizontal shelf of dura that 
lies in the transverse cerebral fissure between the cerebral hemispheres and cerebellum. Dura 
mater is made of two layers that adhere to each other in most places except at dural venous 
sinuses. At the venous sinus the two dural layers let a formation a space that is rich in venous 




Figure 2.6. The meninges of brain [7]. 
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Arachnoid mater is a soft translucent membrane that loosely envelopes the brain. It is 
separated from dura by a narrow subdural space that contains veins en route to the venous 
sinuses. The innermost layer-pia mater is a highly vascular, microscopic membrane that closely 
adheres to the brain while following all of its concavities and convexities. The space between 
pia mater and arachnoid mater is the subarachnoid space (SAS). The SAS contains a 
filamentous network of connective tissue strands called trabeculae, is transvered by blood 
vessels, and contains CSF. Since the pia mater is closely adherent to the brain and arachnoid 
mater  is like a loose fitting bag, the depth of SAS is non-uniform and varies greatly over 
different regions of the brain. Subarachnoid cisterns like cistern magna are formed at regions 
where significant fissures are spanned by arachnoid mater. CSF flows from the fourth ventricle 
into cistern magna.  
2.4 Physiology of intracranial pressure and intracranial hypertension 
ICP is the pressure exerted by the components of the cranial vault. Figure 2.7 is a 
pictorial expression of ICP.  Under normal conditions, CSF is the most significant contributor to 
ICP. Any imbalance in the volume of CSF can lead to an abnormality in the ICP. As per Monro-
Kelly doctrine [1], the volume of blood, CSF, and brain in the cranium at a given time must be 
relatively constant. The cerebral vessels are compressed whenever there is an increase in ICP. 
An elevation of ICP for a short duration of time results in ischemia due to a reduction in the 
cerebral blood flow which in turn stimulates the vasomotor area, increasing the systemic blood 
pressure (i.e. Cushing reflex) [8]. Stimulation of vagal outflow results in bradycardia and 
hypoventilation. The Cushing reflex helps to maintain cerebral blood flow. However this is not 
true for a prolonged period of intracranial hypertension (ICH). Over a certain range, the 
systemic blood pressure rises proportionaly with the rise in ICP. During extended periods of 
ICH , a point is reached where ICP exceeds arterial blood pressure and thus ceasing cerebral 
blood circulation which results in ischemia. Thus, an immediate homeostatic response comes 
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into action to counter ICH. The efficacy of compensatory response depends on the rate at which 
the cranial volume increases. The brain can cope with ICH to a certain extent after which a 




Figure 2.7. Pictoral presentation of intracranial pressure. 
 
Figure 2.8. Effect of intracranial volume on intracranial pressure [9]. 
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As per the idealized pressure-volume curve, a small change in the cranial volume can 
be compensated by insignificant changes in ICP (up till point 1 of the curve). At this stage, the 
intracranial contents are not tightly packed in the cranium and there is a bit more room for an 
increase in the intracranial volume. A critical stage is reached at point 2 of the curve where a 
slight volume increase results in an elevation of the ICP. The intracranial compliance fails after 
point 3 when the pressure-volume curve assumes a steep form. An incremental rise in the 
volume leads to a rapid increase in the pressure. 
2.4.1 Causes of  ICH 
Any factor leading to an increase in the cranial volume could contribute to ICH. Few of 
the disorders that lead to an ICH are, but are not limited to, hydrocephalus, brain tumors, 
traumatic brain injury (TBI), brain aneurysms, sub-arachnoid hemorrhage, colloid cysts, 
meningitis, and Reye’s Syndrome. Head injuries can be closed or penetrating causing the skull 
to be fractured and depressed, tearing the meninges, and the brain itself. Displacement and 
torsion of the brain lead to contusion and intracranial hematoma, causing concussion, 
neurological deficits, and post traumatic epilepsy. The tearing of a middle meningeal artery 
causes bleeding into extradural space i.e. extradural hematoma. An expansion in the size of a 
blood clot compresses the brain thus causing ICH. Sub-dural hematomas are caused by bleeding 
and seepage of blood from the veins stretching across subdural space. Meningitis, inflammation 
of the meninges, from fungal or bacterial source damages cranial nerves and the brain. If left 
untreated can lead to ICH followed by brain herniation and death. Once meningeal pathogens 
enter the subarachnoid space, host defense mechanisms are generally inadequate to control the 
infection [8,10]. Hydrocephalus (Figure 2.9) is the most commonly recognized cause of ICH. It 
can be of communicating or non-communicating type. In communicative type the reabsorptive 
capability of the arachnoid villi is impaired or there is an over production of CSF by choroid 
plexus. The balance between the filtration and reabsorption of CSF leads to an increase to the 
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intracranial volume which results in ICH. CSF also accumulates in the ventricles (Figure 2.9 
[11]) when the foramena of Luschka or Magendie are blocked or there is an obstruction in the 
ventricular system, giving rise to non-communicating hydrocephalus [12, 13].  Few other 
classifications of hydrocephalus are adapted- i) internal and external [14], ii) active and passive, 
iii) acute, sub-acute, and chronic, and iv) normal pressure and elevated pressure [15, 16]. 
Colloid cysts are benign tumors that are found in the anterior third ventricle [17, 18]. They are 
epithelium lined cysts which cause morbidity and occasional mortality due to their location. 
Their presence in the third ventricle might present an obstruction to the flow of CSF into the 
fourth ventricle, leading to obstructive hydrocephalus, ICH, and sometimes intracystic 
hemorrhage. With the imaging tools like CT and MR colloid cysts are generally identified 
without any evidence of hydrocephalus on the scans. Figure 2.10 presents a case study of 35 
year old patient with the diagnosis of colloid cysts in the third ventricle.   
 
 
Figure 2.9. Appearance of a hydrocephalic infant and its CT images. a)The head circumference is nearly 70cm at the 
age of 3 months, b) CT scan has estimated the coronal (AB) and sagittal (CD) diameters of enlarged skull as 301.7 





Figure 2 10. Images of a patient diagnosed with colloid cysts. a) Axial unenhanced CT scan shows a high attenuation 
colloid cyst, b)Sagittal MR image shows the colloid cyst (arrow) [19]. 
 
Any space occupying lesion (tumor, hematoma, or abscess) distorts the brain and 
displaces it downwards, in the direction of foramen of magnum due to ICH. The symptoms are 
headache, drowsiness, vomiting, and blurring of vision. A benign type of ICH is a result of any 
generalized swelling of the brain in absence of a focal space occupying lesion. It is often found 
in women, resenting symptoms of a tumor and is also known as pseudo tumor cerebri. 
A significant reason for death and long term disability due to head injuries and 
pathological conditions is an elevation in the ICP. ICP > 20mmHg is considered a significant 








3. Literature Review  
ICP monitoring can assist in the management of patients with a variety of brain 
diseases. The technique has proven valuable, indeed often lifesaving, in the acute care of 
traumatic brain injury (TBI) [14], hydrocephalus [20], drowning [21], inflammatory and related 
cerebral diseases such as Reye’s syndrome [22], hepatic failure [23], intracranial hemorrhage 
[24-26], and postoperative suboccipital brain tumors [27].  There is a conspicuous need for a 
wireless, implantable ICP monitoring system, as several chronic diseases are associated with 
intracranial hypertension (ICH). Conditions for which chronic ICP monitoring are useful 
include cerebral malignancies (annual incidence 16/100,000 population) [28], obstructive 
hydrocephalus (5/100,000) [29], multiple and complex aneurysms and vascular malformations 
(4/100,000) [30], benign ICH or pseudotumor cerebri (1/100,000) [31], and TBI [32]. Most of 
these patients have headaches and other symptoms suggestive (but not always indicative) of 
raised ICP; continuous access to ICP levels would greatly facilitate their management. In the 
United States alone, these diseases represent approximately 70,000 new cases per year and an 
estimated prevalence of more than 500,000. As per 2006 Center for Disease Control and 
Prevention (CDC) report [33], atleast 1.4 million TBIs occur in the United States each year. 
Yet the incidence of TBI in the active and returning military population is understandably much 
higher [34]. In fact, it has been estimated that approximately 30 percent of those evacuated from 
the battlefield to Walter Reed Army Medical Center have TBI [35]. It is well known that blast 
injuries are a leading cause of open and closed head injuries (including TBI), shell shock, and 
Post Traumatic Stress Disorder (PTSD).In the aforementioned cases of neurological 
disorders, an implant placed during surgery for tumor, hydrocephalus or vascular disease 
would be a useful adjunct to patient care. A burr hole to insert an implant in patients with 
benign ICH could also be justified. 
The development of a medical device encompasses a wide range of technologies to 
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ensure the feasibility of its use in a biological environment. In this work, the attributes that were 
reviewed for the ICP  implant are broadly categorized into-i) features of the implant and ii) the 
materials used to build the implant. The first category outlines the selection of frequency for 
wireless transmission, size of the implant, site of implantation, and the methods of measurement 
(invasive vs. non-invasive). The second category focuses on the interaction of the implant with 
biological tissue. It is critical to thoroughly weigh our options in determining the material 
characteristics of the implant to ascertain the survivability of the implant in a hostile biological 
environment.  
The ICP implant in discussion is designed to operate in microwave frequency range. 
For this reason, it is important to have a good understanding of the biological effects of 
microwave frequencies. A section on the biological effects of microwaves is also presented 
here. 
3.1  Implant features 
Therapeutic and diagnostic applications of radio frequency (RF) and microwave in 
medicine have been a subject of extensive studies in the past [36]-[38]. Medical implants for 
transfer of information at these non-ionizing frequencies have been developed [39]. The 
research accomplishments of using data communication links at microwave frequencies 
between a medical implant and an external unit have been reported by many researchers. The 
resonance characteristics of implanted antennas operating at a frequency band of 402-405 MHz 
and their radiation pattern outside the body have been shown to be favorable for short-range 
medical implants [40]. Poon and co-workers demonstrated that the optimal frequency for power 
transmission in biological media is in the GHz range [41]. Gosalia and his colleagues [42] 
demonstrated a novel approach of establishing a data telemetry link between an implant and an 
external unit at 1.45 and 2.45 GHz band, for retinal prosthesis.  Such medical implants are basic 
components for the success of telemedicine, which refers to the utilization of 
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telecommunication technologies in health care. Telemedicine not only facilitates medical 
treatment and care, but is also gaining increasing popularity in post-hospital patient care [43]. It 
provides expert consultation in remote understaffed locations and advanced emergency care via 
modern telecommunication techniques [44]. Mobile patient monitoring systems using wireless 
implants have been developed to maintain records of patient’s vital signs and history [45], [46]. 
These systems are useful during intra-hospital patient transport, intra-operative procedures, or 
post hospital management of patients.   
The core of our active implantable device for ICP measurement is an oscillator 
operating at the Industrial-Scientific-Medical (ISM) band of 2.4000-2.4835 GHz. The sensing 
component is a MEMS piezoresistive or MEMS capacitive sensor, whose variation with the ICP 
changes the oscillation frequency of an oscillator. The oscillator output is coupled to an antenna 
and can be displayed by an external monitoring unit. There are a number of reasons for 
choosing an oscillator- based implantable unit operating at microwave frequencies. Firstly, the 
oscillation frequency of a well-designed oscillator is very sensitive to the change of its tank 
capacitor if a capacitive sensor is used as part of the tank circuit. Secondly, the microwave 
signal transmitted by a small antenna inside the implant can be detected from a significant 
distance outside the patient. Thirdly, the microwave frequency of 2.4 GHz is high enough to be 
efficiently radiated by a small antenna, but is low enough to avoid significant absorption by the 
implant package and skin [38]. In contrast, the passive (battery-less) Bio-MEMS operating at 
MHz range (e.g. 10-20 MHz [47] or 330 MHz [48]) require transcutaneous inductive links [47], 
[48] for monitoring of the pressure. Since the inductive links operate at near-field, pressure 
monitoring receiver must be placed on the surface of the body (i.e., no remote monitoring is 
possible).  Moreover, such an implant would require large inductors (e.g., 3.7 μH [47] and 150-
200 nH [48]), which would make it MRI incompatible. 
An implantable, wireless method for continuous or intermittent monitoring of ICP aids 
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the management of patients with brain disorders or trauma. Accurate monitoring of the ICP 
following a neurosurgical procedure is a basic requirement for an adequate treatment [49]-[51]. 
Since the intracranial contents exist within a rigid vault (skull), direct ICP measurements require 
neurosurgical intervention, with their attendant risks.  
The pioneering work in ameliorating ICH was done by a machinist out of Philadelphia, 
John W. Holter [52] who developed a one way shunt valve for the treatment of hydrocephalus. 
With further modifications, the valve was later known as Holter-Spitz valve, named after its 
inventors- John Holter and Eugene Spitz. This valve did not measure ICP, but created a one way 
diversion for excessive cerebrospinal fluid (CSF).  
 In the past, various techniques have been developed for estimating the ICP. These 
include lumbar puncture, intra-ventricular catheter, sub-arachnoid screw (Richmond bolt), fiber 
optic transducer tip catheters, and acoustic apparatus. In lumbar puncture, a catheter is placed in 
the spinal sub-arachnoid space, estimating the CSF pressure. This CSF pressure at the lumbar 
level does not give an accurate estimate of ICP. Intraventricular catheters provide more accurate 
pressure transduction, but are erroneous if the catheter is dislodged or occluded. The opening of 
the sub-arachnoid screw is placed right under the arachnoid membrane by penetrating the skull 
and dura mata. The bolt can get easily dislodged and restricts the patient to ICU. The above 
examples outline various modalities of ICP measurement based on the site of pressure sensing, 
such as intra-parenchymal (i.e., within the tissue), sub-dural (i.e., below the dura mata, which is 
the outermost protective layer surrounding the brain), and epidural (i.e., above the dura mata). 
These examples also lack accuracy, and simplicity [53], [54]. The utilization of a fluid filled 
manometer and an external strain gage has been the gold standard for ventricular (ventricles are 
the fluid filled cavities inside the brain) ICP measurement and treatment. However, cannulating 
(i.e., introducing a tube into) the ventricle in cases of brain edema may not be feasible, and it is 
the most invasive method of ICP monitoring that can result in infection and brain injury. 
Epidural pressure monitoring is an attractive alternative to the ventricular approach, since the 
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brain or the CSF are not exposed to the external environment, thus presenting fewer 
complications [54]. Studies have been carried out in the past to gauge the reliability of various 
epidural pressure monitors [53]-[58] and at the same time comparing them with ventricular or 
intra-parenchymal monitors. Sub-dural pressure monitoring appears to be a good compromise 
between the risks encountered in ventricular pressure sensing and the reliability limitations 
posed by epidural pressure sensing (Powell and Crockard [56]). In addition, Powell and 
Crockard [56] also observed a stable and linear relationship between sub-dural and ventricular 
pressure measurements with no drift over time. Pressure in the higher range (>30 mmHg) was 
accurately measured by the sub-dural approach.  Along with the invasive approaches delineated 
above various efforts have been made to monitor ICP in a non-invasive fashion. For example, 
by using ultrasound or near- infrared spectroscopy (NIRS) [59-62]. In one instance, 23 case 
studies were conducted to evaluate the utility of measuring the optic nerve sheath diameter in 
children with shunted hydrocephalus, who were suspected of having raised ICP [59].   Lin et.al 
[60] have described the role of NIRS in the evaluation of ICP. Their work is based on the 
principle that the intensity of diffuse reflection light is proportional to the thickness of CSF, 
resulting in a correlation between ICP and diffuse reflection light.  
 Existing clinical ICP monitoring relies on catheter based systems to record the 
ventricular pressure. This technique restricts the patient to hospital settings, accompanied by 
risks, patient discomfort, and expense. ICP can also be inferred indirectly from neuroimaging 
like computer tomography (CT) and magnetic resonance imaging (MRI) scans [63]. However, 
these methods lack sensitivity and represent only one moment in time during which the scan is 
performed. They also require transportation of the patient out of the intensive care unit (ICU) 
and exposure to ionizing radiation in the case of CT scan. Therefore, neuroimaging and in-
hospital monitoring are unrealistic options for long term and recurring symptoms.   
All the current methods of ICP monitoring have limitations that require wires, cables, or 
catheters emanating from the patient’s head.  These tethers are frequently dislodged by the 
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 Table 3.1, presents a comparison between few of the techniques that are used for ICP 
monitoring and the approach that has been adopted for the development of our ICP implant. 
 
Table 3.1. Comparison of intracranial pressure monitoring modalities. 
CSF stands for cerebrospinal fluid 
3.2  Implant materials 
The safety of a medical device in a biological medium begins with the choice of 
materials that are used in building an implant. In January 2000, National Institutes of Health 
(NIH) reported that 8-10% Americans have some type of implant in their body [69]. The surface 
of an implant that comes in contact with body should be composed of biomaterials. Metals like 
stainless steel, aluminum, titanium, gold, cobalt-based alloys, nickel-titanium alloys  have long 
been used as biomaterials are also approved by the Food and Drug Administration (FDA) for 
use in medical implants[70-73]. Polymeric materials [70] like Ploymethyl siloxane (silicone 
rubber, silastics) has been used in joint replacement, polymethyl methacrylate as cement 
(grout), polyurethane in hip joints, etc. Silicones are applicable at a wide range of temperatures 
(-50 oC to 260 oC) and can mechanically adhere to a wide range of materials. They have low 
tensile and surface peel strengths which indicates that silicones are suitable as structural sealants 





Low Frequency Implants 
(kHz-MHz) 
Our ICP Implant 
(GHz) 
 Long Term ICP 
Implantation 
NO NO YES YES 
 Complete Implantation NO NO YES YES 
 Wireless Implantation NO YES YES YES 
 Distant Wireless Reader 
Range 
NO NO NO (< few inches) YES (up to 0.8m) 
 MRI Compatibility NO NO NO YES 
 Patient Comfort NO NO YES YES 
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than structural adhesives. Typical silicone applications include bonding and sealing of silicone 
based assemblies, coating of components to minimize rough edges, and coating of highly 
flexible assemblies such as endotrachial tubes [74], [75].  Cyanoacrylates (crazy glue) and 
epoxies are known to be effective adhesives and bond well with many materials.  In considering 
materials for a medical implant, several factors are of significance. The material should be: 
i) non-toxic and non-carcinogenic, cause no or little foreign body reaction, and chemically 
stable, 
ii) able to handle stresses in corrosive body environment, and 
iii) able to be fabricated into the desired form. 
Polymeric coatings are applied to medical devices for a variety of reasons which 
include enhancing biocompatibility and biostability, thromboresistance, antimicrobial action, 
dielectric strength and lubricity [70]. Parylene (Poly xylylene or its derivatives) is a vapor 
deposited polymer that is heavily used in medical device industry. The process does not use any 
solvents, plasticizers or surface enhancers and is carried out at room temperature. Parylene 
coatings are completely conformal, produce uniform thickness, and are pinhole free. The 
advantage of this process is that the coating forms from a gaseous monomer without an 
intermediate liquid stage.  As a result, component configurations with sharp edges, points, flat 
surfaces, crevices or exposed internal surfaces are coated uniformly without voids [76]. 
Parylene coatings can resist chemical attack from organic solvents, inorganic reagents, and 
acids and also offers high dielectric strength. It can be coated on  a diverse types of surfaces like 
metals, glass, paper, plastics, ceramics, silicon etc. A properly formulated Parylene is pure, has 
no foreign impurities, and thus does not change the surface properties of the base material. 
Parylene coatings are transparent, have very low thrombogenic properties, and exhibit a 
potential for triggering an immune response [70]. These coatings are also deemed to be resistant 
to the damaging effects of corrosive body fluids, proteins, enzymes, electrolytes, and lipids. The 
coating also acts as a barrier to the passage of any contaminants from the coated surface to the 
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external environment. Out of the four variants of Parylene (Parylene C, D, N, and HT), Parylene 
C and Parylene N are widely used in the coating of medical devices. Further details on the 
chemistry and the deposition process of Parylene are presented in Chapter 4. 
Parylene coatings have been proven effective in coating electronic circuits and silicon 
(micro electro mechanical systems, MEMS) in medical devices. Chen et al. [77], have described 
a microfabricated Parylene based implantable intra-ocular pressure sensor for glaucoma. The 
biocompatibility of their implant was successfully verified in a six-month long animal study. In 
another study carried out by Wasielewski and his colleagues, an intra-operative pressure 
monitoring device was used in total knee arthoplasty in a group of 38 patients [78]. The 
packaging applications of Parylene in the fabrication of medical devices have also been 
elucidated in [79] and [80].  
3.3 Biological effects of microwaves 
Although microwaves are non-ionizing radiations, yet their interaction with biological 
media is usually quantified in terms of its (thermal) absorption in the tissue. The thermal effects 
of microwave depend on the external field as well as the dielectric field inside the body [38]. 
The properties of internal field are affected by a number of factors that include: 
i) Frequency, intensity, and polarization of the external field, 
ii) Dimensions and dielectric properties of the biological tissue under consideration, 
iii) Spatial configuration of the source in relation to the tissue that is receiving the 
electromagnetic energy, and 
iv) Presence of other objects in the surroundings for multipath effects. 
A biological medium is an inhomogeneous and lossy dielectric with complex shape or 
dimensions.  Since a number of parameters are involved in the characterization of the biological 
effects of microwave, it becomes a highly complex problem to model the effects of each 




As microwaves pass through a biological tissue, most or all of its electromagnetic 
energy is converted to thermal energy and the extent of conversion is determined by the 
dielectric properties of the medium and the frequency of the source. The dosimetric measure of 
the energy conversion is defined by specific absorption rate (SAR) which is the rate of energy 
deposited per unit mass of the tissue and is expressed in the units of Watt/kg. SAR can be 
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where, dW is the incremental energy absorbed by the tissue, dm is the incremental mass 
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where, ܧଓഥ  is the peak value of the internal electric field , εo  is the permittivity of free 
space, ε” is the imaginary part of permittivity of tissue, and s is the conductivity of tissue. 
SAR is averaged over the whole body (average SAR) or localized to a small volume 
(local SAR) of 1 g or 10 g of tissue. It is used to quantify the energy absorbed due to the use of 
mobile phones, medical devices, and MRI scans. In United States, Federal Communications 
Commission (FCC) directs 1.6 W/kg to be the upper limit for local SAR when averaged over 1g 





4. Intracranial Pressure Monitoring Implants 
The ideal specifications of an intracranial pressure (ICP) monitoring system have been 
defined in [81]. The system should:  
i) be simple, reliable, and able to function efficiently over a long period of time and under a 
variety of conditions, either continuously or intermittently, 
ii) cause no significant discomfort or risk to the patient, 
iii) minimize trauma or irritation of intracranial structures,  
iv) cause no leakage through the link between the ventricle or the point of interest and the 
monitoring apparatus, 
v) allow for ease of disconnecting the patient to permit other investigational procedures or 
possibility of recording pressure measurements during various diagnostic or therapeutic 
procedures, and 
vi) provide maximum information about variations in the ICP.  
The implants for the monitoring of ICP that are designed by our group are small enough 
to be inserted in a burr hole and also have the following characteristics: 
i) Small: can be implanted by a common neurosurgical procedure, which can be performed 
either during primary surgery or through a burr hole. 
ii) Stable: produce an insignificant drift over the usage time of the device. The device should 
have a maximum error of +/- 2 mmHg in the range of 0-20 mmHg or +/- 10% of the full 
scale in the range of 20-100 mmHg, as per American National Standard Institute (ANSI) 
specifications [82]. 
iii) Compatible with imaging systems: no damage to the device with minimal impact on image 
quality from modern investigational procedures including MRI, CT, and ultrasound.  
iv) Biocompatible: no adverse effects over the lifetime of the device. 
v) Rugged: likely to survive any non-fatal injury. 
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vi) Inexpensive and patient comfort: The cost of the device must be reasonable compared to the 
cost of competing clinical options. An X-ray or  CT scan exposes the patient to enough 
radiation to increase lifetime cancer risk by a fraction of 1%.  An MRI study involves no 
ionizing radiation, but may require sedation and monitoring. 
vii) Others: wireless, simple, rapid and painless interrogation procedure. 
Over the duration of this research effort, a variety of ICP monitoring implants were 
developed, mainly based on three factors i.e., the method of pressure sensing, the site of 
pressure sensing, and the ease of implantation procedure. There are two methods of pressure 
sensing and hence two electronic different designs. An additional factor of classification, i.e., 
the type of animal model for conducting in-vivo studies, was also introduced that only affected 
the size and shape of the implant packaging. The aforementioned classifications are enumerated 
and detailed in this chapter. This chapter also describes the process of measurement from 
pressure transduction to wireless transmission. The last section of this chapter elaborates on the 
selection of various materials in the fabrication of these implants from the point of view of 
biocompatibility. 
4.1 Packaging concept of implant 
The implants are contained in a cylindrical metallic casing to be implanted in a burr 
hole in the skull. The casing has a fixed/adjustable flange or four tabs on the top side which is 
screwed to the skull for a tight fit. The sensor, electronics, and the antenna are assembled on 
printed circuit boards, PCB (FR4, 30 mil thickness).  The numbers of PCBs used in a design 
vary as per the size and shape of the implant casing for a desired type of study. In total three 
configurations were developed as the designs evolved. In all the configurations, the sensor is 
placed at the bottom surface of the implant and the antenna is mounted on the top surface. 
Figure 4.1 shows one of the implants with a two layer design, forming a cage shaped cylindrical 






Figure 4.1. An implant  is shown; a) without the case and b) mounted in the stainless steel metallic case (12 mm 
diameter and 9 mm height). 
 
4.2 Various classifications of the implant 
For a good understanding of the implant characterization and references to various 
types of implants in the upcoming description and discussion, the ICP implants have been 
categorized based on:  
i) The method of pressure sensing, 
ii) The site of pressure sensing, 
iii) The size of burr hole, and 
iv) The nature of intended study. 
4.2.1 Method of pressure sensing  
The choice of a pressure sensor was mainly influenced by its commercial availability as 
the primary focus was to conduct a proof-of-concept study (in-vitro and in-vivo) with an implant 
that was designed and fabricated with commercially available components. The important issues 
of ICP monitoring with the implant i.e., biocompatibility, implant sealing, integrity, pressure 
sensitivity, temperature sensitivity, trans-scalp wireless transmission, scar tissue formation 
(histo-pathology) at the implant and sensor site, and trans-dural versus sub-arachnoid pressure 
sensing were addressed. To perform initial in-vitro and in-vivo tests, a PZR sensor was used 




sensors with the desirable features of size and frequency response over the pressure range of 
interest at the time. At a later stage, implants based on capacitive MEMS sensors were 
developed. Figure 4.2 shows a photograph of the PZR and capacitive pressure sensors. A 
(MEMS) capacitive pressure sensing element is a preferred choice of pressure transduction.   
The PZR sensor has the advantages of availability and lower cost. However, there were major 
disadvantages that were noted in our study and are as follows:  
i) Poor performance repeatability (due to large sensor tolerance, for example, a standard 
deviation of 3 mV for a 69 mV sensor output voltage at room pressure, or 4.5%),  
ii) High sensitivity to temperature variations, and 
iii) Requirement of larger number of components and a signal conditioning circuit that increase 
the power consumption and contribute to poor performance repeatability and temperature 
sensitivity. On the other hand capacitive pressure sensors are small in size; operate over a 
wider range of temperature; and exhibit good linearity and compatibility to CMOS signal 










The PZR absolute pressure sensor, model 3000 series that was used in the initial studies 
was acquired from Merit Sensor Systems, South Jordan, UT. Surface mount and die versions of 
this sensor were obtained for a pressure range of 0-5 PSI, resistance of 3500 Ω. The capacitive 
absolute MEMS pressure sensors, model number SCB10H series were obtained from VTI 
Technologies, Finland. Table 4.1 lists few of the parameters of the PZR and the capacitive 
pressure sensors. The governing equations of the sensor model used in our latest ICP implant, 
are described below [84]. The details of capacitive sensors are emphasized here as the latest 
prototypes of the implant are built with this type of sensor.  
4.2.1.1 Capacitive sensor model 
The governing equation of the capacitance as a function of pressure is  
 
ܥ݉݋݈݀݁ ሺ݌ሻ ൌ ܥ݋݋ ൅ ݎܥ݋ ൅
ܥ݋
1 െ ቀܥ݋݇ ቁ ݌
൅
ܽܥ݋
1 െ ቀܥ݋ܾ݇ቁ ݌
                              ሺ4.1ሻ 
                          
where, Co, Coo, and k are statistical variables that are independent of each other and 
vary from batch to batch and unit to unit with the standard deviations, a, b,  and r are constants 
for a given type of sensor, and p is the applied absolute pressure. 
Functions α (t) and β(t) are described for temperature dependency at constant pressure (p=pref) 
and temperature dependency of sensitivity, respectively.  
 
ߙሺݐሻ ൌ ןଵ ሺܶ െ ܶݎ݂݁ሻ ൅ ןଶ ሺܶ െ ܶݎ݂݁ሻଶ                             (4.2) 
ߚሺݐሻ ൌ  ߚଵሺܶ െ ܶݎ݂݁ሻ ൅  ߚଶሺܶ െ ܶݎ݂݁ሻଶ                                 ሺ4.3) 
 
where, pref =  760 mmHg, Tref= 25oC, α1 is the temperature coefficient of offset (TCO), 
and  β1 is temperature coefficient of sensitivity (TCS). 
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Table 4.1: Characteristics of the PZR and capacitive MEMS pressure sensor. 
Capacitive Pressure Sensor  (30-120 kPa, 225-900 mmHg, absolute) 
Size (length, width, thickness) 1.4, 1.4, 0.85 (+/- 0.05) mm 
Lowest mechanical 
resonance frequency of 
diaphragm 
   450 kHz 
 










ሺ݌ െ ݌௥௘௙ሻ                              ሺ4.4ሻ 
                          
Based on equations 4.1 to 4.4, and the parameters listed in Table 4.2,  the change in capacitance 
for a full range of pressure, i.e ΔC (Cat 120 kPa- Cat 30kPa) has a minimum value of 2.7pF and a 
maximum value of 6.8pF. 
 
 
PZR Sensor (0-5PSI, 0-258.33 mmHg) 
Parameter Value  Units 
Excitation input 3; 5(Nominal) V 
Impedance (input/output) 3500 Ω 
Operating temperature -40 to 150 C 
Linearity 0+/- 0.2 %FSO 
Pressure hysteresis 0+/- 0.1 %FSO 
Thermal hysteresis 0+/- 0.2 %FSO 
Full Scale Output (FSO) 75+/-12.5 at 5V excitation mV  
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Table 4.2: Capacitance-pressure characteristics and parameters for capacitance calculations. 
 
4.2.2 Site of pressure sensing 
The type of implant falls into two classifications (epidural and sub-dural) based on the 
site of pressure sensing. An epidural (ED) implant measures pressure as function of the dural 
deflection. A PZR pressure sensor rests on the dura mater and transduces pressure to voltage. In 
a sub-dural (SD) implant, the pressure sensor is exposed to the CSF in the sub-arachnoid space 
(SAS).  Figure 4.3 depicts the position of the pressure sensor in epidural and sub-dural spaces. 
Irrespective of the epidural or sub-dural nature of pressure sensing, the implant is designed to be 
placed in a burr hole drilled in the skull. The types of burr holes are detailed in the next sub-
section.  
4.2.3 Size of hole drilled in the skull for implant placement  
The initial prototypes are housed in cylindrical cases of approximately 10-12 mm 
diameter. This design was modified to allow for implantation in a smaller burr hole in the skull. 
The second type of hole is 3-4 mm in diameter and is designed to provide access to the CSF in 
the SAS. It must be noted that the sensor and its electronics are contained inside the casing. The 
Capacitance-Pressure Characteristics 
Parameter Nominal Value Units 
A 0.657  
B 1.477  
Coo 0.82+/- 0.22 pF 
Co 3.64+/- 0.22 pF 
K 864 + 200/-164 kPa*pF 
Sensitivity dC/dP 59 +41/-21 fF/kPa 
Non-linearity 0.028 kPa 
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small hole (S) in the skull contains a part of the casing whereas the large hole (L) 
accommodates the entire casing. Figure 4.4 shows the two sizes of hole drilled in the skull along 
with their respective implant casings. Figure 4.5 is a representation of the placement of implants 
in small and large holes. 
4.2.4 Nature of intended study 
The in-vivo studies conducted in this research work were performed in a big animal 
model (swine or canine). However, the casing was later redesigned to accommodate any 
possibility of performing studies on rodent models in any future endeavors. Figure 4.6 shows 
the two types of casings. Casing ‘C’ is symmetric and is intended to be placed in a skull that is 
comparable to a pediatric skull. The symmetry ensures a snug fit of the implant in a burr hole 
and is a good candidate for canine studies. Casing ‘R’ has an asymmetric orientation of the 
nozzle due to a limited availability of space in a rodent skull model. The bulk of the device rests 





















Figure 4.3. . Diagrammatic representation of the device placement in skull; a) sub-dural device implantation and b) 
epidural device in contiguous sections of the meninges. The sensor is exposed to the cerebral spinal fluid in sub-
arachnoid space for sub-dural pressure detection. In epidural detection, the sensor maintains a contact with the dura 






Figure 4.4. Two types of implants based on the size of burr hole in the skull for the placement of implant. 
 
 
Figure 4.5. Implantation of sub-dural implants in a small (S) and a large (L) burr hole. 
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Figure 4.8. Stages of device packaging. 
4.4  Concept of electronic design 
The implants designs were based on a PZR pressure sensor and a capacitive pressure 
sensor. In each case a 2.4 GHz voltage controlled oscillator (VCO, Maxim 2753) was coupled 
to an antenna for wireless pressure transmission. A VCO was used to directly provide power to 
the device transmitter antenna. The VCO implementation was chosen, since it could 
conveniently provide enough power (about -20 dBm)[RThesis] for reliable signal monitoring 
within a range of about 1 m, for a receiver sensitivity of better than -80 dBm. The circuitry for 
each design is detailed here. A simple power management is employed by switching the main 
circuitry on and off with a period of 10 ms and for a duration of approximately 25 µs (0.25% 
duty cycle). The device case (10-12 mm diameter) could host an 11-mA/h rechargeable 3-V 
battery (ML302S). However, for the duration of our long-term experiments, it was decided that 
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an external 3-V battery (CR2032, 220 mAh, 20-mm diameter) be used to supply power to the 
device while it runs at a regulated voltage of 2.5 V. Due to the size limitations the battery would 
be housed in a sleeve adjoining the implant case. It is envisioned that larger size batteries could 
also be implanted next to the implant over the skull. 
4.4.1 Based on PZR 
The implant is run at a supply voltage of 2.8V. A half-closed bridge pressure sensor 
(absolute) in ceramic packaging is exposed to pressure variations. The full scale range of the 
sensor is 0-258.33 mmHg; however the device is designed for 0-100 mmHg range. An 
instrumentation amplifier conditions the signal from the sensor for noise elimination and scales 
it to a linear operating range (1.2V-1.75V) of a 2.4 GHz VCO [85]. VCO output is fed to a chip 
antenna. The antenna nominal bandwidth and center frequency are 120 MHz and 2.450 GHz 
respectively. The receiver antenna is hooked up to a spectrum analyzer to monitor the frequency 
shift and the strength of the signal obtained due to pressure variations [86]. Figure 4.9 shows a 
block diagram of the pressure sensing, transmitting and receiving mechanism. 
4.4.2 Based on capacitive pressure transducer 
The MEMS capacitive pressure sensor is part of an RC circuit of a 700-kHz (varying 
with the ICP) Schmitt Trigger oscillator (Figure 4.10). The Schmitt Trigger output modulates 
the VCO directly. In the ICP device, the VCO is set at a frequency of around 2.44 GHz. The 
VCO generates a burst of 700-kHz modulated pulses with a duration of 25 µs, at a duty cycle of 
0.25%. Figure 4.11 shows the assembly of the implant incorporating the design described above 
and is depicted in Figure 4.10.  At the receiving end, a receiver antenna is connected to a vector 
signal analyzer to record bursts of pressure dependant modulated pulses. A fast Fourier 
transform (FFT) of the received signal gives the frequency which is indicative of the measured 























ion of low p
ed by Warty
A) that is u
sists of a r
te or pin, an
rized for ICP
ing the basic co
lantable tran
mercially ava
6.5 mm2 in s
ever, it was 
anged the 
rofile planar 
, Tofighi et a
tilized in th
ectangular p










































ing and the 
us, design 
 the ICP im
 planar inver
 4.13 [87]. 





















4.5  Materials used in the fabrication of the implant 
The materials selected for fabrication of the implants were chosen in compliance with 
the FDA guidelines.  
4.5.1 Choice of metals 
 In order to make the implants robust, the casings were machined out of metals. Implant 
grade aluminum, stainless steel or titanium was used for the casing.  
4.5.2 Choice of sealants 
Cyanoacrylate and silicone rubber were used as adhesives and sealants for the implant. 
Silicone (Factor II Inc., Lakeside, AZ) was preferred due to the ease of doing any rework during 
the fabrication process. The electronics and the traces PCBs were sealed in silicone to provide 




























in a vacuum chamber to expel any trapped air bubbles. The silicone was sealed parts were let 





4.5.3 Choice of superstrate for PIFA 
Commercially available silicone (εr = 3.7, tanδ = 0.003) [90] was utilized as the 
biocompatible superstrate for PIFA. The optimal thickness of silicone superstrate on the antenna 
was determined by our team and is explained in a Master’s thesis authored by Ms. Ruchi Warty 
[88] as well as in [87]. A detailed account of the simulations and experimentations to determine 
the parameters that are suitable for the use of PIFA as an implantable antenna in the ICP 
implant is presented in [87, 88]. It was concluded that a layer of silicone, 0.5 mm thick would 





















Figure 4.12.  a) Time domain pressure dependant signal, b) FFT of the signal. 
 
 








4.5.4 Choice of biocompatible coating 
The biocompatibility of Parylene (polyxylylene) and its popularity in medical 
applications is discussed in Chapter 3. The last step in the fabrication of ICP implant is to coat 
the implant with Parylene.  Implants coated with 2.5 µm, 5 µm, and 10 µm were evaluated for 
determining the desirable thickness of the coating. Thick coatings are prone to being peeled off 
from the surface of the implant.  A 2.5 µm thick Parylene was deemed to be optimal due to its 
good adhesion to the surface of the implant and negligible effect on the sensitivity of the 
capacitive pressure sensor (discussed in Chapter 5).  
4.5.4.1 Chemistry of Parylene 
Parylene is a polymeric form of para-xylylene. Parylene C has a Cl atom on the benzene 
ring and has favourable properties for biomedical applications due to it slow permeability to 
moisture and corrosive solvents [91], [93]. Figure 4.14 shows the monomeric structure of 



















4.5.4.2 Deposition process 
Parylene deposition occurs in vacuum at room temperature. The key steps (Figure 4.15) 
in the deposition process are: 
i) Vaporization: Heating solid Parylene dimer (di-para-xylylene) until it sublimes into the 
gaseous state. 
ii) Pyrolysis: The heating and cleaving of the gaseous Parylene dimer into a monomer (para-
xylylene). 
iii) Polymerization: The formation of Parylene, as a polymer (poly-para-xylylene), onto the 
substrate at room temperature. 
iv) Condensation: Any unused monomers are trapped on a cold thimble.  






































































Figure 4.16. Chemical reaction involved in the deposition of Parylene [91]. 
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5. In-vitro Evaluation of the Implant and its Characterization  
The intracranial pressure (ICP) implants were evaluated for a number of criteria which 
include the sensitivity to pressure and temperature, repeatability, drift, integrity in water 
medium, and image artifacts on Magnetic Resonance Imaging (MRI) scans. The first section of 
this chapter details the materials and method that were employed to devise various test set-ups 
for testing and characterizing the implant in a laboratory environment. The implants were tested 
in an air medium, followed by tests conducted in water medium. The implants were calibrated 
against the current gold standard (Camino catheters) for monitoring of ICP. Thus each test set-
up was made with a provision for taking parallel pressure measurements with a catheter. A test 
method was designed to determine the wireless range of the implant. A number of MRI 
experiments were done to study the effect of the metal (used to make the implant casing) on the 
MR images. The results and findings from the aforementioned tests are presented in the second 
section of the chapter. The chapter concludes with a discussion on the findings of all the 
experimentations that were carried out in-vitro.  
5.1  Materials and Methods 
5.1.1 Air test set-up 
In-vitro tests of the fabricated devices were conducted in the presence of a Camino 
catheter, used as a reference. These tests were performed in order to establish a relationship 
between the device signal monitored by a spectrum analyzer or a vector signal analyzer  and the 
pressure obtained by the Camino catheter. The tests were also carried out in an air pressure 
chamber at room temperature (19-23 oC). The dry tests were performed inside a sealed chamber 
based on the sphygmomanometer technique of varying and recording the pressure. Figure 5.1 
illustrates the dry in-vitro investigational technique. The pressure chamber is connected to a 
bulb for altering pressure inside the chamber, while a pressure gage displays the chamber 
pressure. The Camino catheter is placed adjacent to the device. The device antenna (chip or 
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PIFA) faces a medium emulating the biological environment (polyacrylamide gel [93]). The 
pressure signal is picked up by a chip antenna [86], [87] followed by a low noise amplifier 





For the purposes of measuring temperature sensitivity of the implants, a heat gun is 
used to elevate the temperature of the implant from room temperature to 60 C. The frequency as 
a function of temperature is recorded at atmospheric pressure. 
The epidural implants were tested for pressure sensitivity in the dry set-up only. The 
epidural (ED) implant was soaked in a water/saline medium prior to any in-vivo study to 
determine the integrity of the implant and its readiness for the in-vivo study. However, the sub-
dural implants with capacitive MEMS sensor (SD_C) were subjected to both dry and wet tests 



















Figure 5.1. Schematic of the set-up based on sphygmomanometer technique for monitoring air pressure
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5.1.2 Hydrostatic test set-up 
Figures 5.2 and 5.3 illustrate the photograph and the schematic of the hydrostatic 
pressure measurement set-up, respectively.  A graduated water column is connected to a bottle, 
which acts as a pressure chamber. The implant is fitted in the pressure chamber which is held 




Figure 5.2. Schematic of the hydrostatic pressure measurement set-up [89]. 
 
positioned in such a way that the overlying confining surface is 1 cm away from the silicone 
covered embedded PIFA. This space is filled by a closely fitted polyacrylamide gel phantom 
[89] or water, emulating the biological environment. The pressure in the system is varied by 
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adjusting the height of the water in the column. The implant is tested in the pressure range 0-40 
mmHg during hydrostatic tests. The pressure in the hydrostatic test set-up was not elevated 
beyond 40 mmHg due to a possible leakage from the water chamber. In order to determine the 
temperature sensitivity of the implant in a water medium, the temperature of the water bath was 
varied from room temperature to 40 oC. Measurements were taken while increasing and 
decreasing the temperature, and maintaining a fixed pressure.  
 
 
Figure 5.3. Photograph of the set-up for hydrostatic pressure measurements. 
 
5.1.3 Microwave transmission 
A study was carried out for quantifying the microwave transmission through a 
polyarylamide gel phantom by using the commercial chip antenna. The PIFA was extensively 
studied in this regard by our team [87, 88]. The details of polyacrylamide gel phantom and the 
set-up for performing measurements on chip antenna are presented here. The phantom electrical 
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property was measured by a coaxial probe to be εr (Permittivity) =50 and s(Conductivity)= 2.2 
S/m at 2.45 GHz.  
5.1.3.1 Polyacryamide phantom 
Skin phantom models are applied in simulation of the tissue behavior to microwave 
frequencies. For equivalence between the phantom and biological tissue three different 
parameters can be considered. Electrical parameters like circuit properties, power transfer, 
internal electromagnetic power deposition, and internal temperature distribution are the most 
significant. In order to have equivalent electrical property, the phantom material is required to 
have real and imaginary parts of permittivity (electrical/ magnetic) equal to that of the tissue 
material to be simulated i.e., scalp.  
Polyacrylamide gel is a convenient and an effective phantom. It has noted advantages as 
following [91]: 
i) The transparency is modifiable and is also good in the optical range. This gel can also be 
conveniently used to simulate optical behavior of tissue, 
ii) It can be easily prepared with a wide range of reproducible electric parameters, 
iii) It is solid elastic, 
iv) It can be molded in any form, 
v) It has convenient mechanical characteristics- self –sustaining without any physical support, 
soft enough to be pierced or stable insertion of needles, wires, thermocouples, 
vi) The recipe ingredients are easily available, and 
vii) The preparation time is 15 minutes and curing time is approximately 1 hour for volume of 
50cc phantom.  
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The only drawback is that this phantom looses moisture over a period of time. 
However, if stored in an air-tight condition its properties are maintained for a longer duration.  
The base material in preparation of the gel is Acryalamide (C3H5NO) which 
polymerizes after addition of water. Gel is doped with sodium chloride (NaCl) for required 
conductivity. Permittivity can be changed by varying the quantity of water by substituting water 
with other liquids like dioxane, pyridine, and ethane diol. The phantom material is cast in liquid 
form. Additional material can be added after polymerization by negligible mixing or subsequent 
diffusion to alter electrical properties. 
5.1.3.2 Phantom recipe 
The base formula for the preparation of polyacrylamide gel is detailed here [90, 93, 94].  
Ingredients of the gel are: 
i) Polymeric acrylamide (C3H5NO), 
ii) Polymerization catalysts: 
MBA   (N, N’-methylene bis-acrylamide  C7H10N2O2 ) , 
TMEDA (N,N,N’,N’ –tetraethyl ethylene diamine (C6H16N2 ) , 
iii) Primer:  Ammonium persulphate (AP), 
iv) NaCl, and 
v) Water. 
Two solutions are separately made and mixed for polymerization to form the 
polyacrylamide gel. They are: 
Solution 1: A total volume of 47 cc is made with  acrylamide,  MBA, TMEDA, NaCl , and 
water 
Solution 2: 1.3% by weight solution of AP in water. 




For our recipe, the gel  contained 9 g of acrylamide, 0.05 g of MBA, 0.25 cc of 
TMEDA, 0.238 g of NaCl, 3 cc of 1.3% ( by weight) AP, and deionised water in a total volume 
of 50 cc. The measured complex permittivity within the desired range of frequency is provided 
in [85]. 
5.1.3.3 Effects of ingredients on the electric properties of the phantom 
i) NaCl: Salt content is a major determinant in the conductivity values of the phantom. With 
no salt added, base conductivity of 0.15 S/m is obtained at room temperature at 2.4 GHz. 
This value is attributed to the presence of AP. 
ii) AP: AP influences the conductivity. With no salt added lower conductivities are created by 
lowering the AP content. However, reducing AP increases the setting time of gel. The 
reaction can be hastened by increasing temperature. If there is no AP present , the gel has 
zero conductivity and the temperature has to be increased to the melting point of 
Acrylamide to cause polymerization to complete faster. Increasing AP and NaCl can yield 
all practical values of the conductivity. 
iii) Acrylamide: This compound controls permittivity.  By altering the monomeric quantity and 
accordingly varying the water content, the permittivity is changed. For example, doubling 
acrylamide, reducing water, and maintaining TMEDA and MBA stoichiometric ratio, 
causes reduction in the permittivity and a slight lowering of conductivity. This would also 
increase the mechanical strength of gel. An increase in the acrylamide content alters the 
transparency of the gel. Higher concentrations of monomer lead to highly exothermic 
reaction, loss of transparency due to inhomogenity, and discontinuities in the internal 
surfaces. 
iv) Water: Water being polar in nature has an effect on the conductivity of the gel, but the 
extent is negligible. Reducing water content causes reduction in the permittivity. 
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v) Non-polar and low permittivity liquids: Water can be replaced by these liquids to alter 
dielectric constant of phantom. These liquids should be solvents for the compounds used in 
the recipe, be non-ionic to avoid any un-necessary contribution to conductivity, be miscible 
with water, and have high boiling temperature to tolerate the exothermic process. Some 
examples are dioxane, pyridine, ethylene glycol (ethane diol).Care should be taken with 
handling certain reagents like dioxane – a harmful chemical. It must be handled under a 
fumehood. It also alters transparency of phantom. Ethylene glycol on the other hand makes 
the material sticky [90]. 
5.1.3.4 Test-set up for measuring microwave transmission through scalp phantom 
    An in-vitro set-up (Figure 5.4) was arranged to emulate the actual scenario of the 
device embedded in a highly absorbent tissue medium. The device was sealed with a 
biocompatible grade silicone, covered by the gel and immersed in water up to the level of 
the phantom. In absence of a phantom, the water level was sufficiently decreased to 
avoid overflowing the gel. It should be mentioned that the received signal strength is 
highly dependent on the polarization mismatch and the multipath environment. The 
receiving antenna was first oriented for the best polarization match and then the 




Figure 5.4. Set-up for measuring microwave transmission through a scalp phantom. Microwave carbon absorbers are 
used to avoid multi-path. 
 
5.1.4 Stability of Parylene coating 
In addition to testing the 2.5 µm thick Parylene coating on a complete ICP implant, the 
coating was also tested in a simplified assembly. The simplified assembly made of only the RC 
Schmitt Trigger configuration.  Note that Schmitt Trigger oscillator (for capacitive MEMS 
implant) generates an approximately 700 kHz signal, whose frequency varies with the pressure. 
The simplified assembly was enclosed by silicone and coated with Parylene before being 
immersed in 0.9% saline. In a complete implant configuration the implant and hence the 
effectiveness of the coating was monitored for a maximum period of 14 days. The simplified 
assembly was immersed and left undisturbed in saline for a duration of 18 months (see section 
5.2.4). 
5.1.5 MRI compatibility test 
Three different designs of the ICP implants, as shown in Figure 5.5, were tested. Firstly, 




environment. The cases were made of stainless steel, aluminum, and titanium for implants #1, 
#2, and #3 (Figure 5.5), respectively. Secondly, general gradient-echo (GRE) and spin-echo 
(SE) images were acquired to observe how the device distorts the magnetic field due to 
magnetic susceptibility  (χm/10-6 cc/mol). A conductive agar-gel phantom (7g/liter agar, 170mM 
NaCl, 6.3mM CuSO4) was prepared for temperature measurements as well as GRE and SE 
scanning, as shown in Figure 5.6(a). Each device was placed in the agar-gel phantom as 
depicted in Figure 5.6(b). Finally, temperature changes near the probe were monitored with 
thermo-optic probes while RF pulses with a time average power of 16.65W were delivered to 
the coil over a period of 2 minutes [96],[97]. The placement of four optical probes (Ch 1- Ch 4), 
for measuring the temperature is also indicated in Figure 5.6.Two temperature probes (Ch 3 in 
the front and Ch 4 on the top of this device) were positioned close to the device and two other 
probes (Ch 1 and Ch 2) were placed far from it. The near and the far probes were placed 
symmetrically in the cuboid gel phantom as indicated in Figure 5.6.  The results of these tests 
are presenting in section 5.2.5. 
 
 
Figure 5.5 The casing material of ICP devices. The casing material of the implant #1(Type SD_Cap_C), #2 (Type 






Figure 5.6. (a) Conductive agar-gel phantom. (width×height×depth=15×7×8.5cm3) (b) One thermal sensor (red spot) 
was placed in front of the device and the other sensor (black spot) was placed at the opposite location. 
 
The MRI compatibility tests were conducted by Dr. Sukhoon Oh in the Department of 
Radiology, College of Medicine, Pennsylvania State University, Hershey, PA. 
 The next section is a compilation of results that were obtained from various 
experimentations conducted on the ICP implants in environments and set-ups described here.  
 
5.2  Results 
5.2.1 PZR epidural ICP implant (PZR_ED_C) 
The performance of two implant prototypes that were tested in air is presented here. 
Figure 5.7 is a plot of frequency versus pressure. Figure 5.10 shows the performance of the 







Figure 5.7. The variation in transmitted frequency as a function of pressure. Tests were  conducted at room 
temperature in air [86]. 
 
 
Figure 5.8. The effect of temperature and supply voltage on the transmission frequency of implant. Tests were 







































T (oC), P-P0 (mmHg, P0= 760 mmHg)
PZT Implant- Temperature and Pressure Variation
Various T, P=760 mmHg 
(atm)




Table 5.1. Measured performance of PZR_ED implant in terms of the frequency (f), received power (PRec), and 
frequency sensitivity, i.e., the rate of change of frequency with pressure (δf /δ(ΔP)), temperature (δf /δT), and supply 





5.2.2 Capacitive MEMS ICP implant 
In total 20 implants based on the capacitive pressure sensor were tested and calibrated 
in an in-vitro setting. Two versions of pressure sensing elements were provided by the 
manufacturer (VTI Technology, Finland) over the course of time. The earlier versions exhibited 
unpredictable behavior in the presence of humidity. Thus a modified version of the sensor was 
later developed by the manufacturer. Out of the 20 devices that were fabricated, 15 were 
designed for large burr holes (10-12 mm, Cap_ED_L_C or  Cap_SD_L_C) and 5 were designed 
for small burr holes (3-4 mm, Cap_SD_S_C).The older version of the sensor was used in 9 
Cap_SD_L_C implants and the rest were built with the improved version. These implants were 
characterized in air and water. A sample time domain signal picked up from the device as 
captured by the VSA is shown in Figure 5.9. To measure the pressure, fast Fourier transform is 
applied to the raw time domain data to determine the Schmitt trigger frequency which is directly 
related to the pressure. The sensitivity (frequency as a function of pressure) varied between 
implants, but was fixed for a single implant. For the sake of conciseness, results from a single 
Parameter  Test conditions Value 
δf/δ(ΔP),  T =  25oC,  Vcc= 2.8 V 0.30 
(MHz/mmHg) 
δf/δT   T = 37oC,  ΔP=0, Vcc= 2.8 V -1.35 (MHz/oC) 
Δf/Vcc   T = 37oC,  ΔP=0 18 (MHz/V) 
f  T = 25oC,  ΔP=0, Vcc= 2.8 V 2.429 (GHz) 
f  T = 37oC,  ΔP=0, Vcc= 2.8 V 2.410 (GHz) 
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and five trials after Parylene coating). The zero pressure sensitivity of the implant in air prior to 
the coating was -0.362 kHz/mmHg, which changed to   -0.336 kHz/mmHg after Parylene 
coating. A frequency shift of 7.48 ± 0.09 kHz (mean ± standard deviation) was observed as a 
result of the Parylene coating (Figure 5.10). 
5.2.2.3 Repeatability in air tests 
At zero pressure, the device demonstrated a standard deviation of ±0.951 kHz which 
corresponds to ±2.6 mmHg zero pressure drift. 
5.2.2.4 Repeatability in hydrostatic tests 
The implant was also tested in the hydrostatic set-up for its integrity and performance 
under variable hydrostatic pressure at a fixed temperature. An average shift of 22.90 kHz from 
the performance in air tests was seen. However, the sensitivity of  -0.373 kHz/mmHg was not 
significantly different from the air tests. The mean frequency at 0 mmHg was 710.73 kHz with a 
standard deviation of ±0.713 kHz, which corresponds to ±1.91 mmHg zero pressure drift. 
Figure 5.10 also shows the performance of the Parylene coated  implant in  different  trials 
(twelve trials for the hydrostatic set-up). It should be emphasized that the implant was kept 
immersed in the hydrostatic set-up for the entire measurement period (twelve days), while the 
data was being collected.  
The Cap_SD_S_C , i.e., sub-dural for small burr holes (see  Figures 4.4 and 4.7, 
Chapter 4) implants were also studied in air and water. As an example, one of the implants 
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1W of power that is delivered to the antenna. As it is described in [87], three PIFAs labeled as 
Antenna_I3, Antenna_II1, and Antenna_I4 were used to evaluate ERP per 1W delivered to the 
PIFA, denoted as E1W. The E1W for the given PIFAs over a range of frequency (2.2 -2.8 GHz), 
with a separation of 27.9 cm between the transmitting (PIFA) and receiving (chip antenna) 
antenna, is shown in Figure 5.12. 
 
 
Figure 5.11.  Received power (PRec) against distance (d), with and without scalp phantom [85]. Measurements 
performed with a chip transmitting antenna at room temperature, atmospheric pressure, and 2.8 V supply voltage to 
implant. 
 
The low values of the evaluated E1W that are obtained here suggest that (as could be 
expected) a medical implant requires a large amount of power delivered to the antenna before 
ERP becomes an issue. Therefore, the SAR limit dictates the maximum device power 
rather than the regulatory ERP (EIRP) value. We have performed finite-element simulation for 
evaluating the SAR, which demonstrates that for the present level of output power (10µW) from 
the ICP implant [85]–[88], the peak SAR level is approximately 4 mW/kg, which is far below 
the regulatory limit of 1.6 W/kg. This implies that this maximum SAR would be reached with 
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dBm (for CW operation). This value corresponds to an EIRP of 0.013 mW ( -18.8 dBm),which 




Figure 5.12. ERP per 1W delivered to the PIFA (E1W) versus frequency for a separation of 27.9 cm between 
transmitter and receiver antennas for three PIFAs [87]. 
 
5.2.4 Effectiveness of Parylene coating 
The efficacy of 2.5 µm Parylene coating was studied on a simplified assembly 
composed of the capacitive MEMS sensor, 82 KΩ resistor (forming RC), Schmitt Trigger, and a 
power management circuit. Three wires were drawn out from this assembly for power supply 
and probing the Schmitt Trigger for the pressure dependant modulating frequency. These 
assemblies were continuously monitored for a period of days, following which the power was 
disconnected, and the assemblies were immersed in 0.9 % saline for approximately 18 months. 
The frequency at the output of the Schmitt Trigger was recorded to be 698.91 ± 0.0128 kHz 
(mean ± standard deviation) and 777.66 ± 0.048 kHz (mean ± standard deviation) for the two 
assemblies. The above standard deviations for the two assemblies correspond to ±0.033 mmHg 
and ±0.127 mmHg respectively, a drift that is considered to be negligible. After 18 months a 
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stable signal was observed at the Schmitt Trigger from both the assemblies. The measurements 
were taken for a period of one hour. The frequency was recorded to be 699.69 ± 0.833 kHz 
(mean ± standard deviation) and 776.42 ± 0.456 kHz (mean ± standard deviation) for the two 
assemblies. The average drift over the period of 18 months was recorded to be 2.1 mmHg and 
3.2 mmHg, respectively.  
5.2.5 MRI compatibility studies 
Implant #1 experienced significant force and torque near the 3.0T magnet, as a 
consequence of that, it could not be held stationary in a gelatin phantom, therefore, further 
experiments were not performed with that implant. Implant  #2 (Al) and implant #3 (Ti) 
experienced very little and no discernable force, respectively. Therefore, implant  #2 and #3 
were suitable for further testing. Significant precipitation was observed on implant #2 during 
phantom preparation, apparently due to interaction between the aluminum casing and the copper 
sulfate in solution (used to shorten T1 relaxation time). When the copper sulfate solution was 
replaced with a 1% gadolinium solution, there was no precipitation. In GRE images, significant 
image distortions were observed near both implant #2 and #3, due to the relatively large 
difference in the magnetic susceptibility of the materials and the medium (agar-gel). The image 
distortions could not be compensated even by using SE sequence as shown in Figure 5.13. The 
magnetic susceptibilities of aluminum, titanium, and water are +16, +151, and -1.04, 
respectively, though the values for aluminum and titanium depend somewhat on how they are 
alloyed [98]. The image distortions precluded the use of MR thermography to measure 
temperature changes near the device during RF heating with methods demonstrated recently 
[96]. Therefore, the temperature changes were recorded using fiber optic thermal sensors 
(OpSens, Canada) near the ICP implant and at a location opposite to the implant (in the absence 
of the implant  SAR and temperature change at these two locations would be identical). The rate 
of temperature change near implant  #2 was 0.100°C/min compared to 0.040°C/min at the 
opposite location, as shown in Figure 5.14(a). Implant #3 (of smaller diameter and titanium 
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casing) showed a very similar temperature change rate (0.045°C/min) to the opposite location 




Figure 5.13. (a) Gradient-echo and (b) spin-echo image of implant #2. Similar image distortion was observed for 
implant #3 (not shown here). Blue rectangle indicates the position of ICP implant. 
 
 
5.3 Conclusions and discussions 
The MEMS capacitive pressure sensors exhibit better performance than the PZR 
sensors. However, the capacitive sensors of desired characteristics were not available at the start 
of this work. The initial prototypes of the implant were built with PZR sensors. These implants 
were used in conducting the preliminary studies to prove the concept of a wireless embedded 





Figure 5.14. (a) Temperature changes (ΔT) near the ICP device #2 (aluminum casing) and (b) device #3 (titanium 
casing). In each figure, red and black lines correspond to red and black spots in Figure 5.6 (b). 
 
 
The MEMS capacitive pressure sensors, subsequently acquired from a commercial 
source, exhibited erroneous behavior when tested in an animal (discussed in Chapter 6). The 
performance of the sensors was sensitive to the changes in humidity. However, the new 
improved sensors, which were believed to be stable under varying conditions of humidity, were 
tested over time in an in-vitro water medium (mimicking the biological environment). The 
reliability of these sensors in the in-vitro experiments was established. The sensors 
demonstrated a corresponding pressure drift (uncertainty) of better than ±0.13 mmHg and ±1.9 
mmHg when tested as part of the Schmitt Trigger (for a  period of 11 days) and the complete 
device (for a period of 12 days), respectively. The device drift can be improved by further 
modification and the integration of implant circuitry.  
Parylene coating was determined to be reliable in maintaining the integrity of the 









6. In-vivo Evaluation of the Implant 
 
In the development of a medical device it is required to show equivalence of response 
between the standard method and any new method developed. For this reason, animal studies 
were conducted with the intracranial pressure (ICP) implant. The overall goal of performing in-
vivo experimentation was to establish a correlation between measurements acquired from the  
gold standard and the ICP implant, and biocompatibility assessment of the implant. This chapter 
describes the protocol for performing animal studies, the choice of animal model, types of 
measurements, and the findings from each animal study. In general, the goal was to implant the 
ICP implant and Camino ICP catheter on the contralateral sides of the frontal bone. Concurrent 
measurements were taken from both techniques for a short duration of time. ICP catheter was 
removed and the implant was monitored for a predetermined duration. All the in-vivo studies 
are individually described here which includes the findings from each study. Under normal 
circumstances, limited variation in ICP is expected in an animal. As a result, a method was 
devised to induce intracranial hypertension (ICH) at the end of one animal study. This enabled a 
comparison between the two methods over a wide range of pressure.   
6.1 Choice of animal model 
The choice of an experimental animal is critical in predicting the outcome of a study in 
human trials. The cranial size of large animal models, such as swine is comparable to that of 
human cranium and can accommodate the ICP implant device as well as the commercial 
pressure monitor. The first animal of choice was a miniature Yorkshire pig due to the fact that 
pigs share many physiological and anatomical similarities with humans [99], [100]. However, 
the presence of large pneumatic cavities in the frontal region [101] of pigs is not favorable of 
ICP evaluation. Consequently, only one in-vivo study was conducted in a pig and further 
experiments were conducted in canine models [56], [102-105].  There is a large body of data 
available in the literature on the use of beagle dogs in ICP and head injury experimentation.  In 
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addition to the size of head, large animals were chosen instead of small animals like rodents or 
rabbits due to a higher probability of reproducing the results from animal studies in humans.  
6.2 Number of animals 
A power based assessment for determining the sample size is considered. The important 
factors to be taken into account are significance criteria (Type I error or α i.e., false positive), 
power = 1-β (where β is the probability of Type II error, i.e., false negative), and effect size (d). 
In this experimental design, no prior knowledge on the long term performance of the ICP 
implant in animals is available. The values for α, which are considered to be practical are in the 
range of 0.05 – 0.1, but not greater than 0.1[106], [107]. As per the available literature on the 
design of animal experiments, the acceptable values of power are from 0.7 to 0.9 [107]. The 
values of α and power recommended by most researchers are 0.05 and 0.8 respectively [106], 
[107]. A discussion on the selection of population effect size is found in [108].  
With the desired values of α, power, and d, the power tables in [109] can be used to 
determine the size of the sample for an experimental design. For our study, we consider d= 0.80, 
α = 0.05, power= 0.80, sample size= 20 (from the power tables in [109]). Thus selecting a 
sample size of 20 animals gives an adequate combination of significance criteria, desired power, 
and effect size for the overall goal of translating this work from animal studies to clinical trials 
in future. However completion of animal studies on 20 animals is beyond the scope of this 
thesis. Consequently, 7 animal studies were conducted as a part of this work. With this sample 
size the power of the study reduces to 0.7 (from the power tables in [109]).  
The animal studies were conducted in compliance with the Institutional Animal Care 
and Use Committee (IACUC) guidelines. An IACUC approved protocol was adhered to while 




6.3 Pre-surgical preparation of animal 
The animal was allowed to get acclimatized for a period of at least one week prior to 
the study. It was ensured that the animal is exhibiting a normal behavior to avoid any 
unpredictable influence on the study. The food intake, excretion, and weight were monitored 
during the acclimatization phase. Food was withheld for 12 hours prior to anesthesia. 
6.4 Anesthesia protocol 
A dose of atropine 1ml (intramuscular) was injected followed by thiopental (5mg/Kg, 
IV). Thiopental caused unconsciousness within 30-45 seconds. An endotracheal tube was 
inserted and the dog was put on a ventilator. Anesthesia was maintained by continuous 
isofluorane (1-2%) inhalation. Buprenorphine was given preemptively at 0.01 mg/kg 
(intramuscular) prior to the surgical procedure. 
6.5 Surgical procedure 
The surgical procedures were carried out by Dr. Francis Kralick, Department of 
Neurosurgery, Drexel University College of Medicine, with assistance from Ms. Kimberly 
Wasko, Department of Surgery, Drexel University College of Medicine.  Anesthesia was 
administered as outlined previously.  The scalp was shaved and prepped using betadine scrub.  
Betadine paint was then used and incisions were demarcated using a sterile skin marking pen.  
A 4 cm incision was made on the left side of the scalp, 1 cm from midline and centered 1cm 
posterior to the coronal suture.  Subcutaneous tissues were dissected using unipolar 
electrocautery.  A self-retaining retractor was placed.  A cutting burr was used on a high speed 
drill to trephine the skull in a circular fashion.  The dura mater beneath the bony opening was 
left intact for epidural studies and punctured for access to the sub-dural space for sub-dural 
studies. Figure 6.1 shows a large burr hole drilled in the skull with intact dura mater for an 
epidural study. Figure 6.2 shows a small burr hole for a sub-dural implant. These figures also 
present a comparison between the two sizes of burr holes. It is worthwhile to mention that the 
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efficacy of the implantation procedure increases many times in the second case, owing to the 
ease and rapidness of drilling a small burr hole.  
 
 





Figure 6.2.  Photograph showing a section of pnctured  dura mater for aceess to sub-arachnoid space in the case of 
sub-dural pressure sensing. CSF can be seen in the sub-section of the picture shown to the right. 
 
 
12 mm burr hole 
Intact dura mater 
4 mm burr hole 




An adjustable collar that was provided with implants for large burr-holes was set to the 
proper depth dictated by the thickness of the skull.  Set-screw were tightened to maintain proper 
depth.  The device was then fixed to the skull with 4 self-drilling, self-tapping 8 mm screws. 
The set-screws for fixing the level of flange are seen in Figure 6.3.  Figure 6.4 shows the self-
tapping screws that fix the implant to skull, and an unsutured incision above the implant that is 
positioned in skull. The scalp was closed using interrupted silk sutures with power leads 
tunneled through the incision for external power supply to the implant.  In later studies, the 
implant package housed a battery for power supply. Attention was then turned to the 
implantation of the Camino subarachnoid ‘bolt”.  The “bolt” was implanted in prescribed 
fashion.  In one of the studies the external fiberoptic cable of the Camino “bolt” was placed 
within a specially designed collar.  The purpose of the collar was to contain the fiberoptic cable 




Figure 6.3.  An empty casing with the adjustable flange. Set-screw to adjust the level of flange for variable skull 





Figure 6.4. Placement of an implant under the scalp. The implant is fixed to skull by self-tapping screws. Note that 
this picture shows a sub-dural implant for a small burr hole. 
 
While the animal was under anesthesia both monitors were tested and provided 
expected data.  Moderate alterations in ventilation rate to produce hypo and hyperventilation 
were made. Hyperventilation causes cerebral vasoconstriction, reduction in the cerebral blood 
flow, and as a result a reduction in ICP is produced. Hypoventilation has a reverse effect leading 
to vasodilatation and a consequent increase in ICP.  Under normal circumstances, the variations 
in ICP are limited and altering the rate of ventilation has a very modest effect on ICP. 
Moreover, the ventilation rates are only altered within safe limits so that the effects are not 
detrimental to animal. Prolonged hyperventilation can cause cerebral ischemia and sustained 
hypoventilation may lead to brain damage by increasing ICP. Thus, the respiratory rate was 
changed over a range of 2-18 breaths per minute. Each rate was maintained for a period of 
approximately 5 minutes while the vital parameters of the animal were also being monitored. 






both monitors and recorded.  Figure 6.5  is a photograph that was taken while simultaneous 
measurements were acquired from the two ICP measuring methods. 
 
 
Figure 6.5. Simultaneous measurements being taken from ICP implant and Camino monitor in an anesthetized 
animal. 
 
The animal was then allowed to emerge from anesthesia and taken to the recovery area. 
Further measurements from the ICP implant were taken daily for the duration of the study. At 
the end the animal was euthanized by an overdose of Pentobarbital (5mg/Kg in 5ml) 
administered intravenously. The implant was recovered; samples of tissue (Figure 6.12) were 
extracted from the site of implantation for toxicity study. 
6.6 Post-surgical medication 
The post-surgical regimen of medication was prepared to counter any risks of infection 
and alleviate distress or pain exhibited by animal. In order to avoid infection, antibiotics 









and Buperenorphine were prescribed for mild to severe signs of distress. The site of incision 
was periodically inspected for any fluid discharge.  
6.7 Induced intracranial hypertension 
For the purposes of evaluating the performance of the ICP implant over a wide range of 
pressure, ICH was induced in the animal. In order to achieve this, sterile, pyrogen free saline 
(mock CSF) injections were administered into the brain of an anesthetized dog. A cisternal 
needle was inserted into the brain to allow infusion of mock CSF to produce a range of ICP. For 
each session, more fluid was injected into the brain to produce a range of ICP between the 
normal level and approximately 80 mmHg (Figure 6.6). For each ICP level, the Camino 
pressure was recorded and compared with the simultaneous reading of the ICP implant. At the 
end of this session, the cisternal needle was retracted. It must be noted that this procedure was 
carried out only once for a single animal study as higher levels of pressure can cause 
irreversible damages to the brain. Thus, it was conducted at the end of a study after which the 
animal was sacrificed. 





Figure 6.6.  Scheme for infusing saline into the brain for inducing intracranial hypertension by increasing the amount 





Animal is acclimated to the new surroundings for a period of at least 1 week 
Anesthetize the animal 
Surgical procedure: 
Complete implantation of ICP implant, and 
Placement of Camino ICP sub-arachnoid  bolt 
Simultaneously measurements are taken from ICP implant and Camino ICP catheter 
Camino ICP catheter is removed and the incision is sutured 
Animal recovers from anesthesia 





measurements for a 
predetermined duration 
Leave the implant in for at least a period of one month 
for biocompatibility assessment
Replace the implant with a new one to take measurements over a 
wide range of pressures by inducing ICH
Anesthetize the animal 
Implant Camino ICP sub-arachnoid bolt, 
Induce ICH, and 
Simultaneous measurements by both the methods.
Euthanize animal 
Recover the implant 
Extract tissue samples for biocompatibility assessment 
No
Figure 6.7. Flowchart describing the sequence of events while conducting an animal study. 
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6.8 Duration and key findings of animal studies 
A total number of 7 out of 20 animal studies (as determined by statistical analysis, 
section 6.2) were conducted. One study was carried out in a pig and six were performed in dogs.  




Table 6.1: Details of animal studies including key findings from each study. 
Key: PZR: Piezoresistive, Cap: Capacitive MEMS, E: Epidural, S: Sub-dural, L: large burr hole, S: Small burr hole. 
 
The findings from each animal study were critical in improving and designing the 
course of next in-vivo experiment in terms of its goals and desired outcomes. The findings from 











Pig         
1 
PZR E_L 4 hours • Feasibility of microwave 
transmission through scalp 
• Pressure as a function of 
ventilation rate 
Dog     
1 PZR E_L 5 weeks • Integrity of Implant 
• Biocompatibility assessment 
2 PZR E_L 24 hours • Correlation between Camino 
catheter and implant 
3 C Cap_L 24 hours • Correlation between Camino 
catheter and implant 
4 C Cap_L 2 months • Implant performance over a wide 
range of pressure  
• Integrity of Implant 
5 C Cap_L 20 days • Correlation between Camino 
catheter and implant 
6 C Cap_S 27 days • Longevity study 




6.8.1 Pig Study 
The aim of this study was to determine the feasibility of microwave transmission 
through scalp [85]. This study was conducted with a PZR_ED_L model for duration of 4 hours. 
At the time of this study, the Camino ICP monitor was not available to us. Figure 6.8 shows the 
implantation in a pig model. Methyl-methacrylate cement was used to hold the implant steady 
in the burr hole. It must be noted that this implant had an external power supply instead of an 
embedded battery. The pressure variations as a function of respiratory rate were recorded and 
plotted (Figure 6.9). Power measurements as function of separation between the scalp and 
receiver antenna were recorded to determine the wireless range of the implant (Figure 6.10).  
 
 















Figure 6. 9.  Estimated ICP as a function of respiratory rate [85]. 
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The ICP varied inversely with the rate of respiration, as expected. The effect of 
hypoventilation is seen as an increase in the pressure. However, at lower values of pressure, the 
pressure curve (Figure 6.9) depicts an overall insensitivity of the device in low pressures. This 
can be due to the contraction of dura at low pressures. Moreover, the pressure sensor surface 
was not in direct contact with the dura because of the ceramic packaging of the pressure sensor. 
This can also lead to the insensitivity of the frequency to ICP.  
6.8.2 Dog 1  
In the subsequent study, the implant previously used in a swine was reused and 
implanted in a canine model for a period of five weeks. A good healing of the scalp overlying 
the implant was observed. Figure 6.11 shows a small protrusion on the dog's head at the site of 
implantation after one week. It should be noted that with the healing of the scalp and the growth 
of hair at the site of incision, the position of the implant or battery is hardly discernible for any 
aesthetic concerns.  
The subject was euthanized and three specimens (Figure 6.12) were obtained for histo-
pathological examination. The specimens were:  
i) Specimen #1: This specimen was from the tissue overlying the implanted implant and shows 
reactive ‘scar tissue formation’. There were abundant lymphocytes (colorless cells that are 
cellular mediators of immunity) within a fibrous matrix. 
ii) Specimen # 2: This specimen was from brain beneath the implant  and shows no 
abnormality.  It shows normal cortical architecture devoid of reactive fibrotic tissue.  There 
are no abnormal cells or necrosis present.  
iii) Specimen # 3: This specimen was from dura mater. One end of the specimen was taken 
from beneath the implanted device.  This is contiguous with dura mater sample remote from 
the device under normal skull.  The specimen demonstrates significant thickening and 
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This implant showed aberrant performance after the study period. No electrical/signal 
testing was performed during this experiment. However, alterations to the design of the implant 







Figure 6.13.  Specimen # 3 showing thickening of dura mater under the implant due to fibrosis and lymphatic 






6.8.3 Dog 2  
The modified epidural implant (including PIFA antenna and a die PZR sensor) was 
implanted in a dog for a period of 24 hours. A standard ICP monitoring catheter was placed on 
the other side of the midline for rapid and continuous ICP measurements, and comparison with 
the wireless measurement. For this particular study a pressure variation in the range of 11-22 
mmHg was achieved by altering the rate of respiration. Readings were taken while the dog was 
anesthetized and being weaned of the ventilator. An r-squared correlation of 0.88 between 
Camino catheter and ICP implant was determined. A plot of Camino pressure versus the 
pressure measured by ICP implant is shown in Figure 6.14. The measurements are less 
erroneous in the pressure range of 10 to 20 mmHg (±2 mmHg) and show a slightly higher 
variation at elevated pressures. High pressures may lead to a forceful dural contact with the 
sensor. This could be the reason for erroneous response of the device at >20 mmHg, since this 



























Implant (PZR_ED) vs. Camino Monitor
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6.8.4 Dog 3 
In a follow up canine study, an epidural configuration with capacitive MEMS was used 
for a one-week study. The results obtained relative to the in-vitro tests and in comparison to the 
Camino catheter pressure monitoring showed a great degree of inconsistency between the in-
vitro and in-vivo implant readings. Moreover, the implant readings were not repeatable for 
different measurement sessions, for which the study was conducted. This was attributed to the 
unstable capacitor response in wet environment. However, a new MEMS capacitive sensor, 
modified to resolve the humidity issue (verified by the manufacturer) was made available to us. 
This new sensor was utilized in conducting further studies. On the other hand, because of 
further issues with the epidural device placement (as indicated by histo-pathological findings), 
the MEMS based epidural device was not studied again. 
The preliminary work on the PZR design paved the way for a better approach in 
designing the system with a MEMS capacitive pressure sensor, while issues like 
biocompatibility, integrity of the device and feasibility of microwave transmission through scalp 
were addressed. The growth of fibrous tissue underneath the device in epidural measurements 
and the variability in the thickness of dura mater led to the decision to move to a more reliable 
sub-dural measurement technique.  
The implants in used the next three dog studies were of capacitive MEMS subdural 
type.  
6.8.5 Dog 4 
The total duration of this study was two months during which two implants were used. 
The first implant functioned for 13 days after implantation. Moderate changes in ICP were 
achieved in an anesthetized animal and the pressure measurements were taken from the implant 
and the catheter at the onset of this experiment. Figure 6.15 is a plot comparing the two 
measurement techniques. A correlation coefficient of 0.98 (r-squared value of 0.96) was 
established between the two techniques. A maximum error of 1 mmHg was determined when 
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the implant measurements were compared to the Camino measurements. The later 
measurements were taken only from the implant for 13 days after which no signal could be 
received. The ICP that was recorded from the implant only, from the second day to thirteenth 
day was in the range of 9-10 mmHg. The malfunction of this implant was attributed to the 
failure of the battery. This implant was left undisturbed till the end of 2 months in the animal for 
biocompatibility assessment. A second implant was implanted right before terminating the 
study. The goal of this procedure was to gage the in-vivo performance of the implant when 
compared with the catheter over a wide range of pressure as shown in Figure 6.16. A pressure 
range of 10-84 mmHg by inducing ICH as described in section 6.7. A correlation coefficient of 
0.998 (r-squared value of 0.996) was established between the two techniques.  A maximum 

































Figure 6.16. Comparison of Cap_SD_L  Implant with Camino catheter for dog 4. 
 
Tissue specimens from this study were examined for any abnormalities. An abundance 
of fibrous tissue matrix was found as expected. 
6.8.6 Dog 5 
This study was conducted with a Cap_SD_L implant. Measurements were taken from 
this implant for 13 days. This animal developed complications due to infection at the site of 
implantation. Serous fluid accumulation due to bacterial infection was also resulted. The animal 
had to be euthanized due to the complications. Figure 6.17 presents a plot of pressure values 
from implant versus pressure measured by catheter on the day of surgery. A maximum error of 
1.34 mmHg was determined when the implant measurements were compared to the Camino 
measurements. A correlation coefficient of 0.98 (r-squared value of 0.97) was established 
between the two techniques. The ICP that was recorded from the implant only, from the second 





























Figure 6.17. Comparison of Cap_SD_L  Implant with Camino catheter for dog 5. 
 
6.8.7 Dog 6 
The last animal study was conducted with an implant (Cap_SD_S) that is designed for a 
small burr hole. The measurements from ICP implant were in good agreement with the Camino 
measurements with a correlation coefficient of 0.988 (Figure 6.18). A maximum error of 1.2 
mmHg was determined when the implant measurements were compared to the Camino 
measurements.  Data was collected from the implant on a regular basis for 45 days. The ICP 
values in a normal active dog were in the range of 8-12 mmHg as shown in Figure 6.19. During 
this period, blood samples were also collected from the dog to test for complete blood count, 
sedimentation rate, and C-reactive protein. The results hence obtained, did not indicate any 














































































The healing of scalp is shown in Figure 6.20. This photograph was taken on day 30 
after the surgery. 
 
 
Figure 6.20. Photograph of dog showing the healing of scalp after 30 days of surgery. 
 
6.9 Test of Correlation 
In order to determine the significance of the correlation coefficients between the two 
modes of measurements that were determined for the animal studies, a two-tailed hypothesis 
test was performed. Consider a null and alternative hypothesis as follows:  
Ho: r =0 (i.e. there is no significant correlation between the paired data) 
Ha: r ≠ 0 (i.e. a significant correlation between the paired data exists) 
The formulae for calculating the test statistics are given by: 
ܶ ݏݐܽݐ݅ݏݐ݅ܿݏ ݐ݁ݏݐ ൌ ݎඨ
݊ െ 2
1 െ ݎଶ
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where,  n is the number of paired data points and  df is degrees of freedom and equals 
(n-2). 
If the p-value is less than the significance criteria, α then the null hypothesis is rejected 
and the alternate hypothesis holds good.  
The T and p-values for all the animal studies are reported in Table 6.2.  With α=0.05 
(section 6.2), all the p-values were below the significance criteria. Therefore, alternate 
hypothesis is accepted and a significant correlation is found between the measurements taken 
from the ICP implant and Camino catheter.  
6.10 Sources of error in ICP measurements 
A number of sources that can potentially introduce an error in the measurement of ICP 
by the implant are identified and enumerated below. The error estimates that are presented here 
are in reference to the implant that is described in section 5.2.2 
i) Averaging error: A number of measurements (three or four) are acquired for each pressure 
point. The mean value of the measurements is considered to be the true value of pressure for 
a given pressure point. For example, the pressure values were in the range of 0.1 mmHg 
from the mean pressure. 
ii) Resolution of Camino catheter: The Camino monitor offers a limited resolution of 1 mmHg. 
In a complete study, the pressure measurements from the ICP implant are taken in two 
steps, i.e., in-vitro and in-vivo. In each step measurements from the implant are compared 
with the Camino catheter. The implant is characterized in reference to the Camino catheter 
in the in-vitro tests. A mathematical function that describes the dependence of frequency on 
the pressure is determined from these tests. Since the catheters do not resolve the pressure 
to a fraction of 1mmHg, an error of ±0.5 mmHg is introduced at the time of in-vitro 
characterization of the implant. Similarly, the implant is compared with the catheter at the 
89 
 
time of conducting in-vivo studies, when a maximum error of ±0.5 mmHg is possibly 
introduced into the pressure measurements from the implant. Since the in-vitro and the in-
vivo measurements are taken at separate instances, the errors at each instance are cumulative 
in the overall two-step ICP measurement process. Thus, a possible maximum error of ± 1 
mmHg could be expected in a complete ICP measurement study that comprises of the in-
vitro and the in-vivo experimentations. 
iii) Temperature uncertainty: In the two-step ICP measurement process, an error could be 
caused due to the fact that the pressure dependant frequency varies with temperature 
fluctuations. However, the temperature uncertainty had a small effect on the overall error in 
the ICP measurements. For example, the temperature sensitivity of one of the implants in 
the in-vitro tests is 0.87 mmHg/oC. The body temperature of an anesthetized animal varied 
by ± 0.2 oC in our in-vivo studies. This corresponds to an error of ± 0.17 mmHg, which is a 
small in magnitude in comparison to the error that is introduced due to the limited 
resolution of the Camino catheter. 
iv) Site of pressure sensing: The fluctuations of ICP that occur internally within the skull 
contribute to the overall certainty with which an ICP monitoring system can measure the 
pressure.  However, quantifying the variations in ICP is beyond the scope of this work. In 
addition, the error in ICP measurements by the implant is estimated in relation to Camino 
catheter. Since both the techniques measure ICP in the frontal region, the effects of the site 
of pressure sensing can be ignored.  
The sources of error described above are independent of each other. Thus, the 
maximum error in the measurement of ICP by the implant would be the sum of individual 
errors. In this case, the maximum error due to averaging, limited resolution of Camino catheters, 






The evaluation of ICP implants in the in-vivo settings provided vital details that validate 
the applicability of this implant in the monitoring of ICP. The practicability of microwave 
transmission through swine and canine scalp is established. It must be noted that dogs have a 
thick temporalis muscle beneath their scalp. In some instances the thickness of temporalis-scalp 
 
 





Correlation df T p-value 
(two-
tailed) 
2 11-22 0.94 5 6.161 0.0016 
4 7-11 0.978 3 8.20 0.0038 
4 16-84 0.998 13 59.20 0.0001 
5 10-30 0.987 6 16.52 0.0001 
6 8-20 0.988 5 15.84 0.0001 
 
complex can be greater than the thickness of scalp in humans. Thus, the implant could 
possibility have a longer wireless readability range than 0.8 meters that was determined from 
the animal studies. The long duration studies on the implant proved its integrity and wholeness 
in corrosive biological environment. Parylene coatings on various implants were impermeable 
to the body fluids and were critical in maintaining the proper performance of the implant. A 
2.5µm thick coating did not have any effect on the sensitivity of the implant.   
Various models of the implant were evaluated and a preference of their use was derived 
from these studies. The thickening of dura mater at the site where the pressure sensor made 
contact with dura was suggestive of a compromise in the overall accuracy of the implant over an 
extended period of ICP measurement. These histo-pathological findings from a five week study 
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in dog 1 underscored the need for sub-dural method of pressure sensing. A reduction in the size 
of burr hole required for an ease of implantation, possibly at the bed-side, was also achieved. 
Thus, a sub-dural ICP implant that requires a small burr hole has a preferred combination of 
implant properties.  
The performance of ICP implant in relation to Camino catheter was determined. A 
correlation coefficient of 0.94 or better was estimated. It is also worthwhile to mention that the 
epidural mode of pressure sensing produced the lowest value of correlation. Thus corroborating 
with the earlier finding that the sub-dural mode of pressure measurement provides a more 
accurate result than the epidural mode. Although the readings from the implant were not 
compared to that of the catheter during long-term studies, yet the implants exhibited a 
consistency in their performance over the duration of pressure monitoring. The pressure values 
for each study were within ±2 mmHg of the normal pressure for a particular animal as was 
recorded by Camino catheter on the first day of the study. Thus it can be inferred that the 
implants did not present any significant drift over the course of measurements.  
The ICP implants invoked a normal immunological reaction by the body to any foreign 
object. A microscopic study of the specimens that were collected from the animals after a long-
term implantation showed the presence of lymphocytes and did not indicate any toxicity due to 
the metal, silicone, or parylene used in the fabrication of implants. The study conducted in dog 
6 with the preferred configuration of the implant (SD_S) produced vital results that could be a 
driving factor for conducting any long-term study with these implants. This particular study had 
a power source (battery) embedded in the packaging of the implant. The effectiveness of the 
packaging proved to be pivotal in preventing any battery leakage and also ensured longevity of 
the implant.   The equivalence of ICP implants to the gold standard for monitoring of ICP was 
established as a consequence of in-vivo evaluation of these implants. The concept of an 
embedded microwave ICP monitoring implant at 2.4 GHz ISM band was demonstrated and 
substantiated by a body of data gathered from conducting animal studies. 
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The thickening of dura mater and its effect on the sensitivity of the implant provided an 
impetus to simulate the relationship between the thickness of dura and the degree of deflection 
caused by certain amount of intracranial pressure that is exerted on dura mater. The details of 
























7. Simulations on Dura Mater 
The formation of scar tissue is part of the healing process after a severe external 
injury, is found around implants in biological tissue, and it accumulates internally after 
injury or surgery. The in-vivo studies that were conducted on the epidural ICP implant 
(described in chapter 6) showed the growth of scar tissue around the implant in addition 
to the thickening of dura mater. The thickening of dura mater can be attributed to 
fibrosis as a reaction to the presence of a foreign body (implant) [110]. The build-up of 
scar tissue can affect the sensitivity and accuracy of an epidural pressure measurement 
system since the pressure is measured as a function of the deflection of dura mater due 
to ICP. In this chapter, some preliminary simulations are shown to quantify the effect of 
dural thickness on its deflection. In order to conduct any simulations, it is important to 
know the mechanical properties of dura mater and scar tissue. The mechanical 
properties of dura mater have been extensively studied by various researchers [111-
114]. However little is known about the mechanical properties of the dura and scar 
tissue complex. A few details of the mechanical properties of dura mater and scar tissue 
are presented here. It should be noted that the work presented here is in its preliminary 
stages and will serve as an opening for a more detailed work in the future. 
7.1 Mechanical properties of dura mater and scar tissue 
Dura mater is a viscoelastic material that possesses viscosity (the relative 
resistance to the ease of flow) and elasticity (the tendency of the material to return to its 
original form after a force is applied to it) at the same time. Anatomically, dura is made 
up of connective tissue –collagen and elastin fibers. The collagen fibres in the inner 
portion of the dura are almost perpendicular to fibers in the outer region [114]. The 
Young’s modulus and Poisson’s ratio for cranial dura mater have been reported to be 
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30-40 MPa and 0.45-0.5, respectively [115] – [116].  Scar tissue is known to have 
greater elasticity that normal tissue [117].  The growth of scar tissue is a dynamic 
process and its mechanical properties change with time. The mechanical properties are 
also dependant on the site of fibrosis due to its adhesion with the parent tissue or foreign 
object. Due to a lack of information on the mechanical properties of scar tissue that 
grows on dura mater, scar tissue is considered to be a part of the parent dura for 
simulations purposes. It is also believed that considering dura and scar to be a 
continuous membrane is an acceptable assumption over long duration of fibrosis.  
   A finite element model of the dura-scar tissue complex is defined in the next 
section. 
7.2 Finite element modeling of dura-scar tissue complex 
A simplified model for simulating the effect of the thickness of dura-scar tissue 
complex is outlined here. The simulations are performed on ABAQUS version 6.6, 
student version. A square section of dura mater (5cm X 5cm) is modeled here. Since 
skull has a curved geometry, a radius of curvature of 15 cm is assigned to the modeled 
section of dura mater [118]. A uniform pressure of 10 mmHg is applied over 25 cm2 
area of dura since the normal range of ICP is 0-15 mmHg. For boundary conditions, the 
perimeter of the model is assumed to be fixed. The normal thickness of dura alone is 
0.3-1mm. The histo-pathology results from an in-vivo study (Chapter 6) indicated up to 
a threefold increase in the thickness of dura mater when a sample of dura mater was 
excised and examined after 5 weeks of implant placement in the skull. For simulations, 
the thickness of dura was varied between 0.5 and 3 mm. Figure 7.1 is a diagrammatic 
representation of the simplified model that is outlined above. 
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The entire segment of the dural model is divided into four sections and each 
section has 196 elements making a total of 784 elements for the segment. An eight 
node, linear brick element with reduced integration and a seed size of 0.0035 is used.  It 
must be noted that the student version of ABAQUS only allows processing of a total of 
1000 elements. For this reason, a linear brick element with small seed size was selected 
over a quadratic hex element of the same size.  
 
 
Figure 7.1. A simplifed model of dura mater. 
 
7.3 Results and conclusions 
The epidural implants were housed in a cylindrical case that was 10-12 mm in 
diameter (Chapter 3). It is assumed that the device is positioned at the center of the 
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dural section that is under consideration here. Therefore, attention is diverted to the 
middle section of the finite element model of the dural section. The stress pattern due to 
ICP of 10 mmHg that is applied uniformly to dura, is shown in Figure 7.2. The 
deflection of 0.5 mm thick dura due to the ICP is shown in Figure 7.3.  
 
 
Figure 7.2. Contour plot showing the pattern of stress as a result of a uniform ICP. 
 
 
Figure 7.3. Contour plot showing the deflection of dura as a result of a uniform ICP. 
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The deflection of the dura-scar complex for various thicknesses as a function of 




Figure 7.4. The change in the deflection as a function of the thickness of dura-scar tissue complex. 
 
Since dura is a viscoelastic material, it is not possible to derive a linear relation 
between the deflection and the thickness of the dura-scar complex. In general, an 
increase in the thickness of dura-scar complex would lead to a reduction in the amount 
of deflection that would be caused by a certain amount of pressure. In other words, a 
build-up of scar tissue would affect the accuracy and sensitivity of an epidural ICP 
monitoring system. Thus further confirming the need to measure ICP in a sub-dural 



























8. Conclusions and Future Work 
 
The technology of ICP monitoring in the research arena has been receiving constant 
attention for decades and significant advancements have been made by various investigators.   
The contributions from researchers from various disciplines that include, but are not limited to,  
sensor technology, wireless technology, biomaterials,  have built a rich pool of background 
information that has been cardinal in designing our research work.  These contributions have 
been detailed in Chapter 3 of this thesis. This chapter presents the uniqueness of our work and a 
summary of the tasks that have been accomplished while developing our ICP monitoring 
technology.  In addition, an account of the recommendations for future work is also outlined 
here.  
8.1 Contribution of this thesis 
The significant contribution of our work is emphasized by its uniqueness and the 
success in conducting animal studies that have answered the concerns that are relevant to the 
development of a medical implant.  
8.1.1 Uniqueness of this work 
The singularity of our work lies in the fact that our ICP implant has been designed to 
operate in the Industrial-Scientific-Medical band of 2.4 GHz. The wireless ICP implants that 
have been reported so far are designed at lower frequencies, for example in the MHz range as in 
[119]-[122]. Moreover, our selection of frequency for wireless communication was also 
recently confirmed by Poon and his co-workers who have theoretically demonstrated that the 
optimal frequency for power transmission in biological media is in the GHz range [41]. 
8.1.2 Summary of the achievements 
Throughout the duration of this research the ICP implant was constantly modified to 
meet the challenges in designing and achieving an optimal combination of the implant features. 
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Few of the challenges were ensuring biocompatibility, longevity of the implant in an animal 
model, repeatability of performance, minimizing the contact area between the sensor and the 
tissue, reducing the size of the burr hole to be drilled in the skull for an ease in the implantation 
procedure etc. The implants were immersed in a hydrostatic pressure chamber for determining 
their integrity in a water medium in the in-vitro environment after being coated by a 2.5µm 
thick Parylene. Parylene coating proved to be a reliable interface between the implant and the 
biological medium. It was tested for a duration of 18 months in 0.9% saline solution and 5 
weeks in an animal model. It was efficient in isolating the implant from the corrosive fluids in 
the body and at the same time protected the MEMS sensor from degrading in wet conditions. 
The performance of the ICP implant was monitored for 12 days in water and up to one month in 
animal studies. In water medium, the drift was less than 2 mmHg. In animal studies, the 
pressure was compared to the gold standard only on day 1 of the study; a correlation of 0.94 and 
better was determined (from four dog studies) between the implant and the Camino catheter 
(gold standard for ICP measurements). A sense of normal pressure for a particular animal was 
gained on this day of the study while simultaneous measurements were obtained from the 
implant and the Camino catheter. In the following days, during the course of an animal study, 
the implant pressure was monitored on a regular basis. The values of ICP were in the normal 
range for a particular animal as was determined on the first day of the study.  
The design of the implant evolved from an epidural to the sub-dural type. It was 
determined from our study and is also reported in the literature that a sub-dural pressure 
monitoring system is a more accurate method of pressure measurement than an epidural system. 
A measure of intra-ventricular pressure has been reported to be the most desirable way to 
quantify ICP. However, a sub-dural method provides a good compromise between the site of 
pressure sensing and the degree of invasion into the brain. In our technique, the pressure sensor 
is placed in sub-arachnoid space where it measures the cerebrospinal fluid (CSF) pressure. In 
addition, no damage is caused to the brain tissue as the pia mater remains intact. 
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In an alternative step of design advancement, the size of the burr hole that is required to 
implant the system was reduced from 10-12mm diameter to 3-4 mm diameter.  This resulted in 
a considerable reduction in the amount of time that was spent in the implantation procedure. 
The ultimate goal would be to miniaturize the implant to allow for a bed-side implantation 
method that would be at par with the Camino catheters. The Camino catheters have to be 
implanted in a sterile condition, but do not necessarily demand a sterile operating room 
environment. They can be easily implanted at the bed-side in an ICU.  
It should be emphasized that our latest animal study was conducted with a sub-dural 
implant that required a 3.6 mm burr hole to be drilled in the skull. On the first day of the study, 
the ICP was measured with both the Camino catheter and our implant, and a correlation 
coefficient of 0.988 was calculated between the two measurements. The normal ICP for the dog 
was in the range of 8-12 mmHg. The catheter was then removed and the scalp was sutured. This 
implant continued to perform for a period of 45 days and the pressure recordings were in the 
normal range for this animal.  
This latest study opens up the possibility of ICP monitoring in ambulatory conditions 
which is beyond the horizon of catheter based systems. It also supports the use of our ICP 
implant in conditions where it is desirable to monitor the pressure for longer periods than 
practically realizable by catheters. An understanding of the ICP trends over a duration of time in 
patients that are recovering from traumatic brain injury, cerebral hemorrhages, or brain tumors 
while they are not restricted to hospitals, would aid in defining their regimen of therapy and  
would also lead to a significant improvement in the outcome. Furthermore, the capability of 
wireless monitoring will facilitate advancement in home health care system and decentralization 
of medicine.  
8.2 Recommendations for future work 
This ICP implant strictly produces a number that represents the CSF pressure inside the 
cranium. The implant has been successfully tested for up to a period of one month which does 
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not necessarily promise its applicability to hydrocephalic conditions. It will be for the benefit of 
a larger population to increase the ambits of our ICP implant applications. A few of the 
possibilities along with directional examples are enumerated here. 
8.2.1 Long-term studies 
In case of chronic conditions like hydrocephalus, an ICP implant that can be left inside 
the cranium as an adjunct to the shunt systems can dramatically influence the course of 
treatment. It can be either incorporated with an existing shunt system or used as an independent 
device to function as a shunt check. In either case, the failure of a shunting mechanism will lead 
to a buildup of ICP which will be detected by the implant and can raise an alarm demanding an 
intervention. The durability of Parylene in an in-vivo environment for one month was 
established as a result of our work.  However, that does not warrant its durability for 
hydrocephalic conditions and remains to be determined. Animal studies should be designed to 
investigate the possibility of extending the application of our implant in the realm of 
hydrocephalus. 
8.2.2 Power management 
For long-term applications an efficient power management scheme should be 
introduced into the design of our implant. One possibility is to integrate a rechargeable battery 
with a recharging mechanism using optical energy. In a different scheme a low power MOSFET 
could be activated by optical energy and would act as a switch to turn on the implant when 
desired. 
8.2.3 Scar tissue prevention 
Protein adsorption on the implant surface is the first step in the series of events which 
lead to scar formation, thus being detrimental to the performance and longevity of the implant. 
The probability of fibrosis can be reduced by hindering the protein adhesion properties of fibrin 
to the implant surface. Non-fouling PEG (poly ethylene glycol ) coatings are protein repellant 
and can be easily immobilized on a titanium oxide surface [123]. A class of co-polymers based 
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on poly (L-lysine)-g-poly (ethylene glycol), PLL-g-PEG adsorbs spontaneously onto the 
titanium oxide layer from an aqueous solution. PEG is immobilized onto surfaces by coupling it 
with functional groups having affinity towards the target surface. Adhesion of PEG is due to 
electrostatic interactions between PEG ions and the oxide layer, thus physiologic pH and ion 
concentration play a significant part. These conditions are fairly constant in CSF and therefore 
the sensor area. 
8.2.4 ICP monitoring and treatment of excessive CSF 
In present clinical practice, the monitoring of ICP and treatment of excessive CSF are 
being conducted as two independent routines. An integrated system that would have an ICP 
monitoring technique in conjunction with a method of treatment will improve the management 
of the underlying cause of the disorder. For example, merging of ICP implant with a CSF 
shunting mechanism. Another application can be based on a combination of ICP implant and a 
reservoir system (for example, Ommaya reservoir) [124]. An elastic expandable reservoir with a 
one way valve in a conduit that tunnels from sub-arachnoid space to the reservoir can be 
implanted under the scalp. An elevation of ICP would cause the reservoir to fill up and the 
patient will suffer from the symptoms of intracranial hypertension. At that time, as the implant 
detects higher levels of ICP, the reservoir can be accessed by a needle to withdraw CSF and 
reduce the pressure. In a more advanced method our ICP implant could be coupled with 
upcoming techniques like “microfabricated arachnoid villi” [125] that mimic the function of 
arachnoid villi found in the sub-arachnoid space. The microfabricated arachnoid villi are one 
way microvalves that control the flow of CSF based on pressure differential.  
8.2.5 Blast injury studies 
It is widely believed that the shock waves produced due to explosions have detrimental 
effects on the central nervous system.  However the relation between ICP and a blast injury is 
not clearly defined. A good understanding of the ICP trends during and after the blast will aid in 
determining the thresholds of blast intensity for various levels of blast injury. Chavko et al., 
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have observed that a direct measurement of the pressure wave inside the brain during an 
exposure to blast has not been reported [126]. They have also reported a direct measurement of 
ICP by a miniature fiber optic probe in rats that were exposed to a blast.  In the same 
publication, the limitations to the use of the probe have been indicated which include a risk of 
infection due to prolonged implantation of the probe.  These studies were limited to 3 days 
owing to a limited applicability of the pressure sensing probe. Our ICP implant can be an 
excellent replacement for these probes for a number of reasons. Firstly, it is a completely 
implantable system with no open incision which reduces the risk of getting infected. Secondly, 
studies can be conducted for a longer duration of time. Thirdly, experiments could be conducted 
on larger animal models that can better relate to humans than rats. In addition, this is a tether-
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Appendix A: List of Acronyms 
ANSI: American National Standard Institute  
CMOS: Complementary Metal Oxide Semiconductor 
CNS: Central Nervous System  
CSF: Cerebrospinal Fluid  
CT: Computer Tomography  
ED: Epidural  
EIRP: Effective Isotropic Radiated Power  
ERP: Effective Radiated Power  
FCC: Federal Communications Commission  
FDA: Food and Drug Administration  
FFT: Fast Fourier Transform  
GRE: Gradient Echo  
IACUC: Institutional Animal Care and Use Committee  
ICH: Intracranial Hypertension  
ICP: Intracranial Pressure  
ICU: Intensive Care Unit  
ISM: Industrial Scientific Medical  
MRI: Magnetic Resonance Imaging  
MEMS: Micro Electro Mechanical Systems 
NIH: National Institutes of Health 
NIRS: Near-Infrared Spectroscopy  
PEG: Poly Ethylene Glycol  
PIFA: Planar Inverted-F Antenna  
PTSD: Post Traumatic Stress Disorder  
PZR: Piezoresistive  
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RF: Radio Frequency  
SAR: Specific Absorption Rate  
SAS: Sub-arachnoid Space 
SD: Sub-dural  
SE: Spin Echo  
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